



07th September, 2020

To
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai - 400 001

Stock Code: 542248

Sub: Annual Report, Notice and Cut-off date

Dear Sir/Madam,

1. We have to inform you that the 24th Annual General Meeting (AGM) of the Company will be held on Tuesday, the 29th September, 2020 at 5:00 P.M. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

2. Pursuant to Regulation 30 and 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III of the said Regulations, we submit herewith Annual Report for the Financial Year 2019-20 ended 31st March 2020 and the Notice convening the 24th AGM, forming part of Annual Report, being sent to the Members by email whose email addresses are registered with the Company/Depository Participant(s). The Annual Report is also uploaded on the website of the Company at www.deccanhealthcare.co.in

3. The Company has fixed 22nd September, 2020 as the 'cut-off date' for ascertaining the names of the Shareholders, holding shares either in physical form or in dematerialized form, who will be entitled to cast their votes at the AGM on 29th September, 2020 in respect of business to be transacted at the aforesaid AGM.

Kindly take the same on your record and display the same on the website of your Stock Exchange.

Thanking you

Yours faithfully

For Deccan Health Care Limited

SHEENA
JAIN

Digitally signed by
SHEENA JAIN
Date: 2020.09.07
15:33:57 +05'30'

Sheena Jain

Company Secretary & Compliance Officer

Factory:

CIN:U72200TG1996PLC024351. Estd:1996.
Address : Plot No: 13, Sector-03, (SIDCUL), IIE, Pantnagar,
Udam Singh Nagar- 263 153, U.K, India
E-mail : info@deccanhealthcare.co.in
Website : www.deccanhealthcare.co.in; www.stayyoungstore.com
Phone : +91 5944 690099

Registered Office:

CIN:U72200TG1996PLC024351.Estd:1996.
Address : 247, 2nd Floor, Dwarakapuri Colony, Punjagutta,
Hyderabad- 500 082, T.S, India
E-mail : info@deccanhealthcare.co.in
Website : www.deccanhealthcare.co.in; www.stayyoungstore.com
Phone : +91 40 40144508



 Deccan
Healthcare
Limited

StayWoW

ANNUAL REPORT

2019-2020





CORPORATE INFORMATION

BOARD OF DIRECTORS & KEY MANAGERIAL PERSONNEL

Minto Purshotam Gupta, Managing Director
Meenakshi Gupta, Director
Hitesh Mohanlal Patel, Director
Narendra Singh, Director
Savita Bhutani, Director
Sheena Jain, Company Secretary

LISTED ON STOCK EXCHANGES

Bombay Stock Exchange Limited (BSE)

REGISTERED OFFICE

#247, 2nd floor, Dwarakapuri Colony,
Punjagutta Hyderabad,
Telangana500082

REGISTRAR & SHARE TRANSFER AGENTS

Bigshare Services Pvt. Ltd
306,Right Wing, 3rd Floor, Amrutha
Ville, Opp.Yashoda Hospital,
Somajiguda, Rajbhavan Road,
Hyderabad - 500082

STATUTORY AUDITOR

Keyur Shah & Co.,
Chartered Accountants

Inside

COMPANY OVERVIEW

- Science of Nutrient Pills
- Message from MD's Desk
- Board of Directors
- Understanding the basics of Vitamins and Minerals
- The Company at a Glance
 - Revenue Growth Movers
 - Consumer Wellness Goals
 - Innovation
 - Supply Chain Control
 - Sales & Distribution Efficiency



Inside

- DHC to Direct Consumer
- Nutrients
- Personal Care
- DHC to International Markets
- Awards & Recognition
- #BEYOUNGBHARAT

STATUTORY REPORTS

FINANCIAL STATEMENTS





LEADING WITH NUTRIENT SCIENCE

Powered by Values

WE ARE COMMITTED TO MEET THE UNMET AND UNDER SERVED NUTRITION NEEDS OF THE BILLION INDIANS. TO ACHIEVE THIS, WE ARE HARNESSING THE POWER OF SCIENCE TO DELIVER INNOVATIVE NUTRIENT PILLS & MEALS THAT TRULY MAKE A DIFFERENCE TO CONSUMERS. IN OUR ENDEAVOUR, WE ARE POWERED BY OUR VALUES, WHICH GUIDE US TO DO THE RIGHT THING EVERY TIME FOR OUR CONSUMERS, CUSTOMERS, EMPLOYEES & THE COMMUNITY AT LARGE.



Message from MD's Desk

CONSISTENT AND SUSTAINABLE BALANCED GROWTH AND VALUE CREATION

2019-20 Performance

I am delighted to report that our strategy, to put energy where it matters for increased focus and efficiency to accelerate growth, is on-point to bear fruit. We are on the journey to place an optimal model for growth. We've made strategic checks to improve efficiency. We invested in increasing our people in the frontline, equipping them with the capabilities required to excel at the job. We reduced spend in noncustomer-facing activity. We optimised our product portfolio, making new product launches and identifying key products behind which we put resources to actively promote. We also have a more structured approach to engaging our trade channel partners, with a dedicated team to engage health care professionals and online marketing team. This approach has helped us serve our consumers and you, our shareholders, better in 2019-20.

With digitisation rapidly remoulding the consumer healthcare landscape, we have been at the forefront of leveraging new and emerging technologies in our business. By embracing the power of Digital, Data & Analytics, we are evolving and aspiring to a state of transformation, whereby highly credible data, digital tools, and experiential learning will significantly improve customer engagement and experience on our e-commerce platform www.beyoungstore.com.

Superiority to Win Consumers

As a science-led company, we have always harnessed the power of nutrition science to help consumers achieve their wellness goals. This year was no different. We recently launched ZnC, an advanced immunity booster, Super Orange chewable delivers a citrus-y burst of essential nutrients including Zinc and Vitamin C, to help make it a super day. We also launched Protein+ Delicious Protein with Natural Coffee, a unique blend formulated from the union of Protein, Coffee and 75 Micronutrients selected directly from the best harvests.

At DHC, we believe that it is not just what you achieve that counts, but how you achieve it. We define winning as delivering consistent and sustainable balanced growth and value creation. We're making gradual but real progress in our efforts to achieve this goal, but we still have work to do.

We are upbeat about growing together with all our partners as this commercial model gains momentum. My deep appreciation to all our shareholders for their continued confidence and support.

The Company in FY 19-20 had revenue of Rs.4224.41 Lakhs and EBDITA of Rs. 1013.18 Lakhs, EPS of 6.42, with a market cap of Rs. 4313.34 Lakhs. The last quarter of the year showed inconsistent demand patterns due-to slow down in the economy given the onset of Covid19 panic. Next year, we expect to continue our positive momentum with the ongoing challenges and impact of Covid19.

Delivering targets requires that we continue to drive even more focus on our strategic choices to win with consumers. The choices we've made to establish and extend the growth of our brands; to drive productivity to fund investments for growth and enhance our industry-leading margins; to lead constructive disruption across the value chain; and to keep our organization structure simple and increase accountability are making a positive difference in our results.

Importantly, these choices are not independent strategies. They reinforce and build on each other and include a strong commitment to social and environmental Citizenship efforts built into the business.

They position us well to deal with near-term challenges from macroeconomic headwinds, trade transformation and anticipated competitive response. Together, they are the foundation for stronger, balanced top- and bottom-line growth and value creation over the short, mid- and long term.

That's our commitment to you, our shareholders — sustainable, market-growing, value-creating growth achieved through superior brands and products that delight consumers and improve their lives. That's our Purpose and that's what the women and men of Deccan Health Care are focused on every day.


M P Gupta
Managing Director



IT'S A

**MILLENNIAL
THING**

**STAY W.O.W
BE YOUNG**



UNDERSTANDING THE BASICS OF VITAMINS AND MINERALS

Vitamins and Minerals play an important role in our daily diet. They are essential nutrients our body needs to stay healthy and work properly at all life stages. They help to digest, absorb and control our normal metabolic cycle throughout the day. Before we go ahead and select any supplement for ourselves, it is important to understand these vitamins and minerals in detail.


Being knowledgeable about the basics of vitamins and minerals and their main functions enable us to understand, what and why are you consuming these essential nutrients on a daily basis and how will it benefit us.

What are Vitamins?

Vitamins are the organic compounds which are required by the body for various thousands of functions in the body. Although they are required in smaller amounts as compared to the protein, fat or carbohydrates, they still do play an essential role for our optimal health. There are total 13 vitamins, Vitamins are classified into two groups, water soluble and fat soluble, and depending on the way they are absorbed in the intestine.

Water Soluble Vitamins: Water soluble vitamins require water to dissolve for the body to absorb them; these vitamins are not stored in the body and need to be replenished daily. B-complex Vitamins and Vitamin C are water soluble vitamins.

Fat Soluble Vitamins: Fat soluble vitamins require fat to dissolve and move through the bloodstream to where they are stored in the liver and fat cells in the body. Fat soluble Vitamins include Vitamin A, E, K & D. Consuming an adequate and balanced diet with full of fruits and vegetables, whole grains, pulses; dairy products can help you get your recommended nutrient intake. Vitamins can be lost or destroyed from the foods we eat through harvesting, transportation, storage of foods, heating or cooking foods, freezing foods, processing foods for packaging, peeling fruits and vegetables (when the vitamin is stored in the outer portions), boiling foods and discarding the water and prolonged exposure to oxygen and supplementation may be the answer to help bridge the gap.



UNDERSTANDING THE BASICS OF VITAMINS AND MINERALS

What are Minerals?

Minerals are crucial to the growth and production of bones, teeth, hair blood, nerves, skin and hormones. Minerals, just like vitamin can be lost from due to various external reasons like soil depletion, procession, food packaging, storing, boiling the foods and later discarding the water etc. There are two types of minerals, major and trace minerals, classified by how much the body needs.

Major Minerals: Major minerals are grouped together because the body needs relatively significant amounts of them. Sodium, potassium, chloride, magnesium, phosphorus and calcium come under macro minerals.

Trace Minerals: Trace minerals are needed in smaller amounts. These include Zinc, Iron, Selenium, Copper etc.

Benefits of Vitamins

Vitamin A: Vitamin A is essential for normal vision, skin and immunity.

Vitamin B: B vitamins help support the metabolic processes in the body, carbohydrate metabolism and energy production.

Biotin (B7): Biotin functions as a coenzyme in metabolism provides dietary support to healthy skin hair and nails.

Vitamin B12: Essential for energy production, red blood cells and neurological function.

Vitamin B Complex: Vitamin B complex directly impacts our energy levels, cell metabolism and brain functions. It prevents infections and promote good cell health.


Folic Acid: Folic acid is essential for proper DNA formation, may support homocysteine levels.

Vitamin C: Vitamin C provides immune support helps absorb iron, essential for healthy bones, teeth, blood vessel and collagen. It also protects against free radical damage.

Vitamin D: Vitamin D is necessary for healthy teeth and bones, enhances calcium absorption and helps improve immunity.

Vitamin E: Functions in the body as the major fat soluble antioxidant, maintains healthy cardiovascular system and promotes healthy skin.

Vitamin K: Vitamin K is necessary for blood clotting, formation of bone matrix and helps transport calcium.



UNDERSTANDING THE BASICS OF VITAMINS AND MINERALS

Benefits of Minerals

Calcium: Calcium is essential for teeth and building bones, involved in muscular and nerve function.

Chromium: Chromium helps maintain blood sugar levels.

Copper: Copper is required for proper nerve cell structure.

Iron: Iron is essential to building blood and transporting oxygen.

Magnesium: Magnesium is necessary for skeletal, nerves; muscle & heart function and for proper Vitamin D function.

Selenium: Selenium is an essential mineral which helps build antioxidant enzymes in the body, supports the antioxidant activity of Vitamin E.

Zinc: Zinc is an essential mineral involved in the majority of metabolic processes in the human body, collagen synthesis; help support immune system and normal reproduction function.

How to choose the right Wellness Goal?

WOMEN: Health for women focuses on prenatal health, immune function, digestive health and menopause. Multivitamins often include calcium, folic acid, protein and iron.

MEN: Health for men focuses on areas such as immune function, prostate and reproductive health. Most men should also avoid supplemental iron.

AGE: Nutrient needs are different for those age 50 plus as well as children and teens.

SPECIAL NEEDS: Do you follow certain dietary restrictions? Perhaps you are a vegetarian or need to pay close attention to the level of dietary sugars. Perhaps you are pregnant or nursing.

LIFESTYLE: Are you active? Do you get enough fruits and vegetables?

Deccan Health Care At a Glance

Deccan Health Care Limited [DHC] is a BSE-SME listed company incorporated in 1996.

DHC was incorporated with a purpose to Research, Develop, Compound, formulate, Manufacture and distribute Consumer healthcare products to PREVENT AND CURE diseases arising out of nutrient deficiencies.

DHC was founded by bio- chemist scientist Minto P Gupta to fulfil his dream of a 'disease free body', positive ageing and reducing disease burden.

DHC through its journey has built assets.

A UNIQUE DISTINGUISHED NUTRACEUTICAL PRODUCT PORTFOLIO SERVING 52 CWG [CONSUMER WELLNESS GOALS]

Input Materials Own Source of High Value ANI's, sung indigenous technology and in-house control of SOP's for outsourced cultivation, cleaning, processing, extraction, freezing, concentrating. Well established quality driven input material supply chain



1

WHY NUTRIENT PILLS AND MEALS?

Everyone irrespective of age or physical state should take them to improve their Quality of Life. We need a variety of nutrients each day to stay healthy, including calcium and vitamin D to protect our bones, folic acid to produce and maintain new cells, and vitamin A to preserve a healthy immune system and vision.

DHCL Nutrient Pills contain nutrients and other healthy substances not found regular food diet, which work together to keep us healthy. We can't get the same synergistic effect from daily food alone. Taking certain vitamins or minerals in higher-than-recommended doses may even interfere with nutrient absorption or cause side effects that's why RDA is the most essential indicator.

2

WHAT IS QUALITY OF LIFE?

It is the standard of health, comfort, and happiness experienced by an individual at all ages. It observes life satisfaction, including everything from physical health, family, education, employment, wealth, and the environment.

3

WHY PHYTONUTRIENTS?

PHYTONUTRIENTS ACT AS POWERFUL ANTIOXIDANTS

Phytonutrients are plant based compounds which are rich in antioxidants and perform a role in neutralising free radical damage. Being a key ingredient in DHCL nutritional food pills and meals they offer additional nutritional benefits to the vitamins and minerals helping you meet your RDA. Phytonutrients—plant nutrients—are found in a variety of colorful fruits and vegetables, protecting plants from physical stress and oxidation. Taking nutrient pills with phytonutrients provides a range of health benefits for your body.





Product Manufacturing Efficiency

We leverage the power of science through new innovations in both preventive and curative consumer healthcare to boost the quality of life.

By foraying into new identified wellness segments, creating products that people value, making them widely accessible and operating efficiently, we aim to truly make a difference to consumers.

Lean Innovation: We're accelerating learning speed and quality and delivering significant benefits in time and cost. There is more focus on the most important markets, and modestly faster growth in these markets will create significant value.



Manufacturing Process

- Installed the best-known plant and machinery equipment, from reputed vendors.
- FSSAI; AYUSH; PAI [FDA] Approved and Licensed Factory
- WHO GMP, ISO, GMP compliant
- Multi Dosage form capabilities: Tablets, Capsules, Liquids, External Preparations
- Highly automated and 'No Contact' facility
- Specialised Liquid filled capsule manufacturing facility
- Regular implementation of International levels SOP's for cGMP & GLP
- Regular Periodic Preventive Maintenance to ensure minimum breakdown and production stoppage
- Higher than standard yields of finished products least process loss
- Own highlight efficient compounding and formulations reducing input costs

REVENUE GROWTH MOVERS

REVENUE CHANNELS

- ➔ **Deccan to Direct Consumers [D2C]**
- ➔ **Deccan to International Markets – Export [D2E]**
- ➔ **Deccan to Private Label Marketing Partners [D2B]**
- ➔ **Deccan to Resellers [D2R]**
- ➔ **Product Development fees**

Customers recognise our efforts in online execution. For the fourth year in a row, BEYOUNGSTORE has been ranked the #1 consumer healthcare store. We've reached #1 in each key performance area in this independent consumer assessment: strategic alignment, people, category development, consumer marketing, trade & shopper marketing, supply chain and customer service.

Led by our key priorities of Innovation, Performance, Trust, we will continue to fast-forward to the future with our consumer-centric scientific way of thinking and execution.

ZEE BUSINESS AWARD

India's Fastest
Growing
Nutraceutical Brand



Revenue Products

- ANI [ACTIVE NUTRACEUTICAL/ HERBAL INGREDIENT]
- RTC [REDY TO CONSUME PRODUCTS / FINISHED DOSAGE FORMS]
- NUTRACEUTICALS & HERBALS [FSSAI], AYURVEDIC [AYUSH], PHARMACEUTICALS [PAI]
- Products for 52 Wellness Goals
- Products for 9 Self Care Health Goals
- Branded Generic Pharmaceutical Products

Revenue From Customers

- Direct Consumers
- Over the Counter Consumers Influenced by Retail Sales Points



—

TELL US
YOUR
WELLNESS
GOAL,
AND
WE WILL
PROVIDE
YOU THE
RIGHT
NUTRIENT
SOLUTION.

CONSUMER WELLNESS GOALS

Top Consumer Needs Served

- Hair Fall
- Deficiency in RDA of Multi Micronutrients
- Prostrate health and male
- Infertility
- Eye health
- Pre and Antenatal MMN
- Delay Menopause
- Skin and beauty
- Body Pains and Aches / Fibromyalgia
- Gastric Disorders / Discomforts
- Low Immunity / Falling sick too often [Post COVID19 this CWG has gained momentum]

OUR REASON FOR BEING IS SIMPLE. WE EXIST TO BOOST QUALITY OF LIFE, STAY W.O.W. TO HELP US REALISE THIS BELIEF IN OTHERS, WE FOLLOW THE SIX VALUES OUR BUSINESS IS BEING BUILT UPON: TEAMWORK, INTEGRITY, RESPECT, ACHIEVEMENT, RESPONSIBILITY AND COURAGE.

The best of nature and science

Our products combines the best of nature with the best of science to provide vitamin, mineral and nutrients pills and meals designed to fill nutritional gaps in consumers' diet on RDA values.


Pure, safe and effective

No one in the world cares or invests as much as DHC does to ensure the purest ingredients, manufactured in the safest way so that people can have confidence in their nutrient pills and meals. We know that nothing matters more than our consumers' health, and the health of their family. That's why we go above and beyond, sourcing our ingredients right from the farm.



FORMULATING THE RIGHT NUTRIENT WITH THE RIGHT RDA

For more than half a century, RDAs have served as the chief components for nutrition policy worldwide, playing dominant roles in the task of meeting the known nutritional needs of healthy people. However, by the 1990s, a number of important developments had occurred that dramatically altered the nutrition research landscape and ultimately transformed RDA. Among them were the significant gains made in scientific knowledge regarding the link between diet, health, and chronic disease, and the emergence of advanced technologies that could measure small changes in individual adaptations to various nutrient intakes.



APPROACH TO NUTRIENTS

Once appropriate wellness goals have been identified for individuals, these must be translated into a nutrient pills that is acceptable to the individual and such he/she is willing to consume. Factors such as nutrient needs and physiological, lifestyle, and health characteristics may alter nutrient requirements.

WE ARE EATING TOO MUCH OF THE INADEQUATE THING, AND NOT ENOUGH OF THE RIGHT NUTRIENTS.

The goal of assessing an individual's nutrient intake is to determine if food intake is meeting the person's nutrient requirements. Assessment of dietary adequacy for an individual is difficult because of the imprecision involved in estimating an individual's usual food intake and the lack of knowledge of an individual's actual nutrient requirements.

Quantitative Approach to Dietary Assessment of Individuals

In-house innovation summarises how nutrients function in the human body; based on the selection of indicators of adequacy on which to determine nutrient requirements; the factors that may affect how nutrients are utilised and therefore affect requirements; and how nutrients may be related to the prevention of chronic disease across all age groups in various demographics..

1500+

Product Portfolio

A growing body of evidence indicates that an imbalance in macronutrients (e.g., low or high percent of energy), particularly with certain fatty acids and relative amounts of fat and carbohydrates, can increase risk of several chronic diseases.

The right nutrient intake levels can produce a range of benefits. For example, one criterion, or indicator, of adequacy may be the most appropriate one to use when determining an individual's risk of becoming deficient in the nutrient, while another criterion of adequacy may be more applicable to reducing one's risk of chronic diseases or conditions, such as certain neurodegenerative diseases, cardiovascular disease, cancer, diabetes mellitus, or age-related macular degeneration.

It is also important to note that each reference value refers to average daily nutrient intake.



Innovation

Nutrient Formulations

1

Science of understanding requirements

Reflects the individual to-individual variability in requirements. Variability exists because not all individuals in a group have the same requirements for a nutrient, even if the individuals belong to the same life stage and gender group.

2

Statistics of establishing nutrient inadequacy

The outcome of a calculation that compares an individual's usual (long-term) intake to the distribution of requirements for people of the same life stage and gender group; used to determine the probability that the individual's intake does not meet his or her requirement.

3

Development of essential nutrient guide

Based on the research suggesting role of nutrient inadequacy in chronic disease, as well as information to ensure sufficient intakes of other essential nutrients, an essential nutrition guide has been established. A key feature of the guide is that it has a lower and upper boundary. Intakes that fall above or below this range appear to increase the risk of chronic disease and may result in the inadequate consumption of essential nutrients.

WHY TRUST OUR NUTRIENT PILLS AND MEALS?

DHC IS COMMITTED TO CONTRIBUTING TO LOCAL FARMLAND COMMUNITIES IN INDIA ACROSS THE HIMALAYAN RANGE, WHERE WE GROW AND HARVEST PLANTS USING SUSTAINABLE, CHEMICAL-FREE METHODS. IN FACT, DHC PRIDES IN BEING THE FRONT RUNNER TO GROW, HARVEST, AND PROCESS MATERIALS THEREBY FOLLOWING AN END-TO-END INTEGRATED APPROACH, ALL MADE IN INDIA.



SUSTAINED INDUSTRY-LEADING GROWTH WITH MARKET-DRIVEN COSTS, PROGRESSIVE DEMAND AND NEW CONSUMER ACQUISITION

➔ Commercial Model

To deliver on our strategy to put energy where it matters for accelerated sustainable profitable growth, a commercial model has been put in place. As part of this strategic model, our product portfolio has been optimised to ensure that our priority wellness goals get greater attention. Measures have also been taken to make operations dynamic and drive improved efficiency.

INDIA'S 50
Transformational Brands

➔ Digital transformation

We are riding the digital wave and have transformed our ways of working. Our leap into the future covers all aspects of our business, with implementing data and analytics driving our customer insights, to artificial intelligence, advanced technology platforms and Customer Relationship Management (CRM) tools, making it easier to achieve focussed goals.




PERFORMANCE

Science-based multi-channel consumer engagement

We engage our consumer with high-quality scientific knowledge about wellness and quality of life. In addition to our internal health care experts, we have also trained our Product Information Personnel (PIP) who understand the science behind our products. To strengthen our focus on science, DHC incentivises our Sales Influencers (SI) on the basis of their efficiency to educate; guide and promote DHC products to target groups. Real-time information support is also given to our SI and PIP through calls, group meetings and on-going interactive learning sessions.

We are reaching our consumer through their preferred channels, which include webinars, e-mails, text messages and virtual calls, among others, in addition to our face-to-face in-gym, dieticians interactions. The first-ever BEYOUNGSTORE e-commerce portal and a specialised website on the wellness goals that features Nutrition Goals, Condition Specific Goals, Ingredient Focus Goals and Daily Care Solutions to address specific consumer goals the millennial Genx consumer is looking for.

**WE'RE CREATING A
SYNCHRONIZED NETWORK
BASED ON REAL-TIME
DEMAND SIGNALS TO SERVE
THE EVOLVING
WELLNESS GOALS
OF CONSUMERS**



The opportunities to gather insights from data are endless and have a profound impact on our ability to drive higher performance. Under our improved marketing model, we are thus accelerating the use of highly credible consumer research data, data analytics and digital tools across our operations. We increased the hiring of experts in digital technology and market analytics this year. As part of our data analytics programme, we are unifying silos of 250,000 registered consumer data on BEYOUNGSTORE and acting upon it to translate them into actionable insights. Finally, by transforming consumer insights into strategic action, we are confident of significantly improving the engagement and experience for our SI & PIP and realise the full potential of our nutrient pills and meals for our consumers.

1000+ MILLION
**Servings consumed
by consumers**

➔ DHC to direct Consumer

- A network of PIP [Product Information Personnel] to educate; guide and promote Deccan products to target groups
- A network of SI [Sales Influencers] to influence sales of Deccan Health Care products to target groups
- An e-commerce website and last mile service supply chain Direct from factory and thru Home Shoppe to serve consumers [B2C]
- Registered consumers on e-commerce platform over 250,000 mostly in Hindi speaking states of North and East India

➔ DHC to International Markets

- Direct Supply arrangements in international markets Kenya and Mauritius
- Indirect supply arrangements to more regulated international markets like USA & Portugal

➔ DHC to Resellers





- Area wise distributor network of resellers
- A network of Sales team to serve the distributors

➔ DHC to Private Label Partners

- Prominent Private Label Partners with extensive sales and distribution skills, include Practicing Dieticians, Nutritionists, Personal Trainers, Modern wellness store clusters, Home sellers' groups, women societies.
 - Factory resident private label contract specialists
-

strength from quality & innovation

OUR INNOVATION HUB AND TEAM MEMBERS ARE TAKING CONSUMER FEEDBACK AND INNOVATION TO THE NEXT LEVEL. WE NEVER REST ON PAST ACCOMPLISHMENTS, WE BUILD ON THEM. WE ARE DILIGENT AND INVENTIVE IN OUR APPROACH TO MAKING DHC PRODUCTS AND DIGITAL EXPERIENCES BETTER FOR OUR CONSUMERS.



growth strategy

THE FIVE ELEMENTS

NUTRITIVE PRODUCTS

Products so good, consumers recognize the difference



IMPROVED PACKAGING

Packaging that attracts consumers, conveys brand equity, helps consumers select the best product for their needs, and delights consumers during use



ONLINE EXECUTION

With the right content, assortment, ratings, reviews, search and subscription offerings.



BRAND COMMUNICATION

Product and packaging benefits communicated with exceptional advertising that makes you think, talk, laugh, cry, smile, act and buy – and that drives category and brand growth.



CONSUMER VALUE

These elements presented in a clear and shoppable way at a compelling price



⊕ BEYOUNGSTORE

52 Wellness Goals

better, faster, and stronger

CONSUMER LIFESTYLES ALONG WITH GROWING INFLUENCE OF GLOBAL TRENDS ARE NOW CHANGING THE FACE OF WELLNESS AND MAKING NUTRITION AWARENESS A PART OF A CONSUMER'S EVERYDAY LIFE. DURING THE NEXT THREE YEARS WE ESTIMATE THAT THE INDIAN WELLNESS INDUSTRY WILL GROW AT A CAGR OF 20% TO REACH INR 875 BILLION. IN INDIA, WELLNESS IS A CONCEPT WHICH HAS BEEN IN VOGUE SINCE ANCIENT TIMES. TRADITIONAL SCIENCE AND HEALTH PRACTICES LIKE AYURVEDA AND YOGA HAVE PROPOUNDED THE CONCEPT OF MENTAL AND BODILY WELLNESS. MOST OF THE ANCIENT WELLNESS CONCEPTS HAVE LARGELY FOCUSED ON THE BASIC NEEDS OF AN INDIVIDUAL WITHIN THE NEED HIERARCHY, NAMELY A FOCUS ON HEALTH, NUTRITION AND RELAXATION. WITH THE PROGRESS OF TIME, WELLNESS AS A CONCEPT HAS TAKEN UP A MULTI-DIMENSIONAL DEFINITION, ENCOMPASSING THE INDIVIDUAL'S DESIRE FOR SOCIAL ACCEPTANCE, EXCLUSIVITY AND COLLECTIVE WELFARE. CHIEFLY INFLUENCED BY CHANGES IN SOCIETY AND IN THE LIFESTYLES OF INDIVIDUALS, THIS CHANGE HAS ALSO BEEN ACCELERATED BY EXTRANEIOUS FACTORS LIKE GLOBALISATION AND A GREATER AWARENESS OF THE NEED FOR MEETING WELLNESS GOALS AMONG INDIVIDUALS.

A young population and an increased consumer focus on wellness make the nutritional supplement category very attractive. Breaking down consumer wellness goals into a manageable wellness plan can be the difference between aspiration and realisations. Every day, we make choices about the food we eat and our lifestyles. We make choices for ourselves and our families that make healthy and active now, and enjoy life to its fullest in the future. The right nutrition promotes and supports social, physical, and mental wellbeing for everyone, at all ages and stages of life. DHC has designed 52 wellness goals based on extensive consumer interaction and research that ultimately help consumers meet RDA- the estimated amount of nutrients per day considered necessary for the maintenance of good health. Vitamins and minerals are often called micronutrients because your body needs only tiny amounts of them. Yet failing to get even those small quantities virtually guarantees disease. DHC's nutritional solution ultimately help in consumers making healthier lifestyle choices. Be Young- a strong- growth e- commerce store (www.beyoungstore.com)- offers consumers a broader range of nutritional products across a wider geographic technical and commercial capability in house.

DHC TO DIRECT CONSUMER



DAILY PERSONAL CARE

Your lifestyle. Stress levels. Exercise. Everything affects your skin and hair. Selected by our experts for their roles, inspired our consumers. Get nutrient goodness in your daily routine



NUTRITION GOALS

The power of nature's own ingredients. When life shows no signs of slowing down, intelligent formulation - designed exclusively for the lifestyle needs at every stage of life



CONDITION SPECIFIC GOALS

Scientifically formulated, customised regimens designed to help customers achieve specific health and wellness goals



INGREDIENT SPECIFIC GOALS

The power of nature's own ingredients to achieve the targeted goal. Because getting the right nutrient doesn't have to be complex



**THE SCOOP ON
BE YOUNG™ - PROTEIN+
DELICIOUS PROTEIN
WITH NATURAL COFFEE**



BETTER, FASTER, AND STRONGER

Adding protein powder to a glass of milk or a smoothie is a simple way to boost your health. After, all, protein is essential for building and maintaining muscle, bone strength, and numerous body functions. And many older adults don't consume enough protein because of a reduced appetite.

Eating enough protein is not just for athletes or would-be Schwarzenegger types. It is necessary for a healthy immune system and required for organs like your heart, brain, and skin to function properly. The nutrient is also touted for its ability to help control appetite and enhance muscle growth.

BE YOUNG™ - Protein+ Delicious Protein with Natural Coffee, An unique blend formulated from the union of Protein, Coffee and Nutrients selected directly from the best harvests. A symphony that gives a unique wellness: a perfect balance between nutrition and taste, a pleasantly prolonged flavour after tasting. Be Young Protein+ Delicious Protein with Natural Coffee is a unique sugar-free combination of Whey Protein & Natural Coffee with the goodness of 75 Micronutrients.

This product is the blend of High Quality Protein-Whey providing essential amino-acids important to support healthy muscles. It also contains B Vitamins known to support energy release and Iron to help reduce tiredness and fatigue. The beauty of choosing a blend containing Protein with coffee & 75 Micronutrients (16 Vitamins, 13 Minerals, 22 Amino-Acids and 24 Natural Extracts) is that it provides triple benefit of protein's nutritional value for growth, recovery, maintenance of muscles and overall complete health.



HAIR NUTRITION

Complaints about hair fall, weak brittle hair with poor strength? Hair thickness, dry scalp and premature greying are common concerns. Most of the Men & Women especially in India complain of hair issues owing to the lack of right nutrition. Product range formulated with most essential vitamins needed for healthy hair and to control hair fall and hair loss and aids in hair growth as well. Expert support for healthy hair.

DAILY NUTRITION & ENERGY

For daily health, product range is a combination of Vitamins, Minerals and Ginseng in appropriate RDA formulations. Helps improve physical and mental performance, prevents stress & fatigue and helps in improving overall health and vitality. Fight fatigue with a choice of energy nutrients.



DIGESTIVE NUTRITION

Contains key enzymes used in your body to break down proteins, fats, and complex carbohydrates. It provides a potent array of gut goodness that are designed to adapt to a variety of stomach acid pH conditions and provide powerful digestion. a good way to possibly fix tummy problem by allowing a more complete digestion of food, creating a smoother ride for what your body wastes. We all need a healthy digestive system.

SKIN NUTRITION

Comprehensive daily nutritional range that combines our most advanced formulas to support beauty from the inside out. Adequate intake of essential nutrients such as biotin, lutein, and amino acids, along with important antioxidants, help support beautiful hair, skin and nails. Hair, Skin & Nails Formula - A specialised formula featuring nutrients that support normal cell growth in the hair, skin and nails matrix.



BONE & JOINT NUTRITION

Bone health is important for us all. With Orthomega, Ostohealth, get extra support for your entire family – a specially-formulated source of Calcium to help maintain normal bones combined with important co-factors including Vitamin D, Zinc and Magnesium. The science of good bone structure. No more joint pains.



PROTEIN DAILY

Protein is an essential macronutrient to build and maintain your muscle mass. Our protein requirements depend on many internal and external factors. A protein requirement of a sedentary person is different as compared to an athlete. Supplementing can be a good option for people who don't get enough protein through diet alone. Enhance your muscle building workout with our range of performance.





Nurtient based cleansers, creams, serums, and oils are proven to perform.

Great skin is not simply a matter of DNA – your nutrition level and daily habits, in fact, have a big impact on what you see in the mirror.

Give it Time: The science behind skin-care products has come a long way but there’s still no such thing as an instant fix – you need time to reap the benefits. With any skin-care product, apply in order of consistency – from thinnest to thickest. For example, cleanser, toner (if you use it), serum, and then moisturizer.

Think of your skin-care routine as consisting of four main steps:

Nourishing – Get your RDA nutrients

Cleansing – Washing your face.

Toning – Balancing the skin.

Moisturizing – Hydrating and softening the skin.

The goal of any skin-care routine is to tune up your complexion so it’s functioning at its best, and also troubleshoot or target any areas you want to work on. Beauty routines are an opportunity to notice changes within yourself. We scientifically formulate and rigorously test skincare products, from moisturisers to cleansers, exfoliators, anti-aging treatments, and more. Each has been thoroughly evaluated or tested by the Lab’s scientists for efficacy and safety.

For our testing, we send label-masked products from hundreds of brands to a panel of thousands of women across the country and solicit real, unbiased feedback from consumers with a range of skin types. We also take scientific measurements in the Lab using instruments to evaluate the results, such as the Corneometer, which measures skin’s moisture levels, and the Complexion Analyzer, a digital imaging device that can track changes in skin, including the size and depth of wrinkles, pore count, and dark spots.



1 Gentle Skin Cleanser

BE YOUNG™ - Revolution™
NUTRIENT Face Wash New 19

With a powder-fresh scent and suds, topped our Beauty Lab's face wash test for cleansing thoroughly yet leaving skin soft. Several testers remarked that it was gentle and great for sensitive skin. "It didn't overdry, strip or irritate," one raved.



2 Smart Brightening Serum

BE YOUNG™ - CELEBRITY
Nutrient Brightening Serum

Scoring points for softening, firming, brightening, evening tone and minimising pores and brown spots, this formulation was the clear winner in the Beauty Lab's serums test.



3 Advanced Omega-3 Hair Oil

BE YOUNG™ -
Omega-3 Hair Oil Nutrition

Flax and Jasmine oil formula hydrated better than 15 other top performers in the Beauty Lab's hair oil test. "Very luxurious," it left hair "soft without being greasy," a tester said.



4 Rapid Clean Teeth

BE YOUNG™ - Revolution
Omega-3 Toothpaste

Naturally scented with herbals and blended with nourishing botanicals like laung oil, this toothpaste is specially formulated containing Omega-3 fatty acids was mildest on gums and best at whitening of the teeth.



DHC TO INTERNATIONAL MARKETS



PERFECTING THE RDA NUTRITION BASED ON DEMOGRAPHIC RESEARCH DATA OF WELLNESS GOALS

Our innovation team relies on multiple quality measures to help ensure our products meet the highest standards. Our experts perform multiple tests each month and quality evaluations each year to guarantee the purity, safety and effectiveness of our products.

STAYYOUNG is a scientifically curated nutrition-focused nutrient system that supports all-day health from the inside out. This has been developed on extensive consumer research and feedback of target population based on their country specific RDA guidelines and requirements of nutrients on the basis of their physique, body structure and lifestyle needs. This is a complete nutrition management line designed to fit consumer's lifestyle. We export to Africa, Soviet, USA and other countries across the globe.

AWARDS & RECOGNITION

AWARDS AND ACCOLADES



Top-100 SMES in India, SKOCH Order-Of- Merit awarded by Sameer Kochar, Chairman, SKOCH Group

Best Fastest Growing Online Nutrition Store, Associate Chambers of Commerce & Industry of India Certificate of Excellence

Fastest Growing SME of the year- Large Size, SME Business Excellence Awards Certificate of Excellence

Amongst Best 50 SME Companies to Invest in 2019, Dalal Street Investment Journal

International Gold Star Awards For Talented Personalities, Global Achievers Foundation

Honoured as Speaker in the Scientific Session, 70th Indian Pharmaceutical Congress, organised by IPCA

Deccan HealthCare among top brands, Hans News Service

AWARDS AND ACCOLADES



India's 50 Transformational Brands, Winning category - Wellness Products &

Top 50 transformational business leaders 2019 at House of Lords British Parliament and the Westminster conference centre, London

Certificate of Appreciation for Supporting Gender Diversity in India, Asian Women Leadership Summit

Sustainability Solution Provider of the Year 2019, India Sustainability Summit & Awards

Leader with a Purpose Award, Transformance India Leadership Summit & Awards

The Marketing Mastermind 2019, India's 50 Transformational Brands

Most Promising Business Leaders of Asia 19-20, The Economic Times

Women Entrepreneur of the year 2019, Business Connect Magazine

AWARDS & RECOGNITION

CEOs
OF THE YEAR 2023

DECCAN HEALTH CARE LIMITED
STAY WOW, STAY HEALTHY WITH DECCAN HEALTHCARE LIMITED THAT ENSURES QUALITY OF LIFE

Deccan Health Care Limited
"Stay WOW"

Mohit Gupta | Business Connect

MOHIT GUPTA

What we eat influences our body to a great extent that can either add quality or subtract it from our life, depending on the nature of our diet. Deccan Healthcare Limited upholds the standards of life by providing qualitative nutritional products. The roots of this colossal organization were entrenched in the founding philosophy, "We believe boosting Quality of Life is as simple as eating an apple every day." Building brands on this ideology, they work hard every day to make quality nutritional products and services, which help people to live life up to its full potential every day. Quality Of Life (QOL) lies at the heart of their philosophy.

They divide life into four convenient consumption categories based on age or life of 2000 days with each life stage of 500 days. They meet stringent product guidelines as framed by FSSAI, and their products are formulated and manufactured within the ambit of the environmental guidelines laid out by FSSAI with stringent quality control measures. This ensures that their products meet the highest industry standards.

DIFFERENT FROM THE REST
DHCL sources high quality ingredients in all its products and sources food based materials from farms, which are organic. Many of these farms are in the high altitude areas of the Himalayas where sustainable farming practices are followed, thereby nullifying the chances of contamination. They bring in pure raw material from the best of farming practices. DHCL sources, growing, harvesting, and processing plants, milk, and seeds on farms where no pesticides are used. Many of these farms use organic growth promoters like plant leaves, etc. Their safety and potency are assured through strict quality control and sustainable practices. The quality and result of products lie in its high concentration of beneficial amino, oligosaccharides, and nutritional value ingredients, which are extracted right from the raw materials. Their product has extracted from traditionally grown herbs and leaf, which contains unique and assured levels of active ingredients and nutrients based on RDA, which provide the nutritional health benefits just one or two sips a day. All of this makes their nutritional solutions truly potent.

WHY SPECIAL NUTRITIONAL PILLS AND WHY?
Everyone irrespective of age in physical state should take nutritional pills and needs to boost their "Quality of Life". They need a variety of nutrients each day to stay healthy, including calcium and vitamin D to protect their bones, folic acid to process and maintain iron, and vitamin A to preserve a healthy immune system and vision.

DHCL Nutrient Food Pills contain nutrients and other healthy substances not found in regular food diet, which work together to keep us healthy. We can't get the

same synergistic effect from daily food alone. Taking certain vitamins or minerals in higher-than-recommended doses may even interfere with nutrient absorption. DHCL offers that's why they have innovated nutritional solutions based on RDA that is the most essential indicator.

REDSHAPES VALUES IN THE COMPANY
Any day of the year founded by Deccan Health Care Nutrient Food Pills and Meals, says they believe in the Company every day, and you are bound to hear "STAY WOW, STAY HEALTHY". These simple words define the inherent belief that craves them. They have believed - it is trusted as not only the biggest accomplishment but the biggest responsibility as well.

"STAY WOW" reflects its commitment to WOW - Wealth, Of, Wellness. In these times, choosing material success and spending wealth on medical expenses restricts the quality of life as you grow. Success at the cost of quality of life is no success. Updating knowledge with pace and innovation ensures that all humans shall boost the quality of life with their Nutrient Food Pills and Meals.

RESEARCH AND DEVELOPMENT
From state-of-art innovation center and manufacturing, analysis of each raw material, DHCL sources the best in nature through science, helping all consumers connect to nature every day. This helps their formulas to closely evaluate the Recommended Dietary Allowance (RDA) to provide nutritional solutions get on the path toward optimal nutrition. And all the improved Quality of Life has to offer.

DHCL sources the inherent goodness of nature through the brilliance of advanced science to help them all connect to nature and provide the right nutrition you need every day to achieve improved Quality of Life. Since 1996, they have innovated scientific processes in-house based on the recommendations of the scientific panel and scientific committee at respect of the RDA values for various micronutrients.

INSPIRING MESSAGE TO THE READERS!
To inspire the readers of Business Connect, Mohit Gupta says, "The fastest way to build your business is to build your confidence. Why? Because when you develop a true confidence, you're able to take risks and risks come when you're scared. You're able to show up, increase your visibility, and put out your offers consistently without worrying about judgment or rejection. When I focused on the fact, I discovered a sense of confidence, which I'd never experienced before. After helping hundreds of clients not only experience the same but also increase their revenue five-fold after time I've learned an strategy will work as well as first having the confidence to adopt that strategy."

MOHITA GUPTA
Chief Business Officer, Deccan Healthcare

With the ever-increasing digital penetration, Asia is placed uniquely to provide a platform to demonstrate consumer healthcare in form of increased penetration with smart pricing as the base, while efficiently redefining, customer-centric markets across the globe. This is in line with UN's Third Sustainable Development Goal (SDG) - "Ensure healthy lives and promote well-being for all at all ages". The current pace of digital innovations in consumer healthcare in Asia, covered through data-driven insight into social impact, (given the large population base), can help address a unique business model for improved health, nutritional interventions in this ever-growing market.

THE ECONOMIC TIMES
AND THE OSCAR GOES TO...

Building a Unified Asia
Leadership is about handling complexities

AN ASIAN GROWTH RECIPE
Asian change-makers share their ideas for a unified Asia

THE IMPORTANCE OF INDIA-Singapore relations

MOHITA GUPTA
Chief Business Officer, Deccan Healthcare

With the ever-increasing digital penetration, Asia is placed uniquely to provide a platform to demonstrate consumer healthcare in form of increased penetration with smart pricing as the base, while efficiently redefining, customer-centric markets across the globe. This is in line with UN's Third Sustainable Development Goal (SDG) - "Ensure healthy lives and promote well-being for all at all ages". The current pace of digital innovations in consumer healthcare in Asia, covered through data-driven insight into social impact, (given the large population base), can help address a unique business model for improved health, nutritional interventions in this ever-growing market.

AWARDS AND ACCOLADES

Award For The Fastest Growing Nutraceutical Brand, Zee Business - National Healthcare Leadership Congress & Awards

Sustainable Product Innovation Award, World federation of CSR and World Sustainability Congress

Brand of the Year Health Supplements, The CEO Magazine

Fastest growing online nutrition store, ASSOCHAM Nutraceutical Excellence Award

Best Wellness Brand - by ASSOCHAM Nutraceutical Excellence Award

Fastest Growing Online Nutraceutical Store, CIMS Medical Nutrition & Wellness Awards



#BEYOUNGBHARAT

We Envision a World where Every Individual, Sick or Well, has Meaningful Access to Information and Nutritional Solutions to Counter Kuposhan



Promoting healthy RDA nutrients to prevent and control diet-related discomfort, disability and disease. The public awareness campaigns use a range of different awareness-raising techniques through these channels, ranging from materials with information to more sophisticated techniques, like social marketing, or using components developed in the psychological sciences, such as the Social Cognitive Theory. Initiatives have been taken in awareness campaigns more specifically getting the right RDA based nutrients. Team works to raise awareness on balanced diets and increased levels of physical activity. An internal study found that the average household diet in 2019 had significantly higher micronutrient intake, increased consumption frequency of promoted RDA nutrients and greater dietary diversity than 2016.

According to the World Health Organization (WHO), of the 57 million global deaths in 2008, 36 million, or 63%, were due to non-communicable diseases (NCDs), principally cardiovascular diseases, diabetes, cancers and chronic respiratory diseases (WHO, 2011a). Nearly 80% of these deaths occur in low-and middle-income countries. Deaths from NCDs are projected to continue to rise worldwide, with the greatest increases expected in low-and middle-income regions.

An unhealthy diet is one of the key risk factors for NCDs. For example, inadequate consumption of fruit and vegetables increases the risk for cardiovascular diseases, high salt consumption, high consumption of saturated fats and trans-fatty acids, a range of dietary factors.

TEAM BEYOUNGBHARAT



Teamwork is the ability to work together toward a common vision. The ability to direct individual accomplishments toward organisational objectives. It is the fuel that allows common people to attain uncommon results. At BEYOUNGBHARAT mission we focus on our mission "kuposhan hataoo kushiyan lao", providing health - wellness- youth empowerment to Indians.

TEAM BEYOUNGBHARAT



NOTICE

Notice is hereby given that the Twenty fourth (24th) Annual General Meeting of the Members of Deccan Health Care Limited will be held on **Tuesday, 29th September, 2020**, at **05:00 P.M.** Indian Standard Time through Video Conferencing (VC)/ Other Audio Visual Means (OAVM), to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2020, together with the Reports of the Board of Directors and the Auditors thereon.
2. To appoint a Director in place of Ms. Meenakshi Gupta (holding DIN: 00574624) who retires by rotation, in terms of Section 152 (6) of the Companies Act, 2013 and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS:

3. To consider re-appointment of Mr. Hitesh Mohanlal Patel (holding DIN: 02080625) as Non-Executive Director of the Company for a period of one (1) year effective from 05th September, 2020 and in this regard, pass the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Section 152 and other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or enactment thereof for the time being in force) [the Act], Mr. Hitesh Mohanlal Patel (holding DIN: 02080625) who was re-appointed by the Board of Directors of the Company, on the recommendation of the Nomination and Remuneration Committee of the Board of Directors at their meeting held on 05th September, 2020, be and is hereby re-appointed as a Non-Executive Director of the Company liable to retire by rotation, to hold office for a term of one year effective 05th September, 2020”.

4. To consider and if thought fit, to pass with or without modification(s), the following resolution as **Special Resolution**:

“RESOLVED THAT subject to the provisions of Section 14 and other applicable provisions, if any, of the Companies Act, 2013 the Articles of Association of the Company be and hereby amended by inclusion of the following clause on page no. 44 under Clause no. 152 (4) “Dividend and Reserves”

“Notwithstanding anything contained in the Articles of the Company, but subject to the provisions of the Companies Act, 2013 and all other applicable rules of the statutory authorities and the Rules framed by the Board of Directors of the Company in this behalf as amended from time to time by the Board, it shall be open for the Members of the Company who hold the equity shares in the Company to waive/forgo his/their right to receive the dividend (interim or final) by him/them for any financial year which may be declared or recommended respectively by the Board of Directors of the Company. The waiver/forgoing by the Members, his/ their right to receive the dividend (interim or final) by him/them under this Article shall be irrevocable immediately after the record date/book closure date fixed for determining the names of Members entitled for dividend. The Company shall not be entitled

to declare or pay and shall not declare or pay dividend on equity shares to such Members who have waived/forgone his/their right to receive the dividend (interim or final) by him/ them under this Article.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized severally to file necessary e-forms with the Registrar of Companies, Hyderabad, in applicable e-Forms and to do all such acts, deeds and things as may be necessary to give effect to the above resolution.”

Place: Hyderabad
Date: 05.09.2020

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Sd/-
Sheena Jain
Company Secretary
(ACS: 52795)

NOTES—

1. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (“the Act”) relating to the special business to be transacted at the Annual General Meeting (AGM) is annexed hereto.
2. In view of continuing COVID-19 pandemic, Ministry of Corporate Affairs (MCA) vide circular dated 5th May, 2020 read with circular dated 8th April, 2020 & 13th April, 2020 and Securities and Exchange Board of India (SEBI) vide its circular dated 12th May, 2020 (collectively referred to as Circulars) permitted holding of AGM without physical presence of the members at the venue. In compliance with these Circulars, the 48th AGM of the Company will be held through VC/OAVM only without physical presence of the members at the venue. The Members can attend and participate in the AGM through VC/OAVM only. Further, the Company will be availing remote e-voting/ e-voting system for casting vote during AGM from Central Depository Services (India) Limited (CDSL).
3. Pursuant to the Circular No. 14/2020 dated April 08, 2020 read with Circular No. 20/2020 dated May 05, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM and hence the proxy form is not annexed to this notice. However, the Body Corporates are entitled to appoint authorized representatives to attend the AGM through VC/OAVM and participate thereat and cast their votes through e-voting. Since, the Members are required to attend and participate in the AGM through VC/ OAVM only, therefore attendance slip and route map are not annexed to this notice.
4. M/s Keyur Shah & Co., Chartered Accountants, having Firm Registration No. 141173W, allotted by The Institute of Chartered Accountants of India (ICAI), Chartered Accountants, the Statutory Auditors of the Company will hold office until the conclusion of the 28th Annual General Meeting of the Company to be held in the year 2024. Pursuant to the notification dated May 7, 2018, issued by Ministry of Corporate Affairs, the requirement for ratification of appointment of Statutory Auditors by the shareholders at every Annual General Meeting has

been done away with. In view of the above, ratification by the members for continuance of their appointment in the ensuing Annual General Meeting is not being sought.

5. Institutional/Corporate members are requested to send at investors@deccanhealthcare.co.in or upload on VC/ OAVM portal, a duly certified copy (PDF/JPEG format) of the Board Resolution authorizing their representative to attend and vote at the Annual General Meeting, pursuant to Section 113 of the Act.
6. As per Rule 20(2) of Companies (Management and Administration) amendment rules, 2015 vide Notification Dated 19th March, 2015, A Company Listed under chapter XB (Companies listed on SME exchange) or chapter XC(Companies listed on institutional trading platform without IPO) of ICDR regulations, 2009 and having its equity Shares listed on a recognized stock exchange, is out of the ambit of E- voting in its General Meeting and DECCAN HEALTH CARE LIMITED is a BSE SME Listed company and E-Voting is not applicable.
7. The Register of Members and Share Transfer Books of the Company will remain closed from Thursday, 23rd September, 2020 to Tuesday, 29th September, 2020 (both days inclusive) for the purpose of the AGM.
8. The Company's Registrar and Transfer Agent (RTA) for its Share Registry Work (Physical and Electronic) is Bigshare Services Private Limited, having its office at Bigshare Services Pvt. Ltd 306, Right Wing, 3rd Floor, Amrutha Ville, Opp. Yashoda Hospital, Somajiguda, Rajbhavan, Road, Hyderabad - 500082
9. Members can avail of the facility of nomination in respect of shares held by them pursuant to the provisions of Section 72 of the Act. Members holding shares in electronic form may contact their respective Depository Participants for availing this facility.
10. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their Depository Participant for the shares held by them in electronic form.(As Companies 100% shareholding is in Dematerialized form)
11. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in the Securities Market. Members holding shares in electronic form are therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts.
12. Details under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and in terms of Secretarial Standard-2 in respect of the Directors seeking appointment/ re-appointment and fixation of remuneration at the 24th Annual General Meeting are annexed hereto as Annexure I to this Notice which forms part of the explanatory statement. Requisite declarations have been received from the Directors seeking appointment/re-appointment. The Independent Directors of the Company has been appointed for a consecutive term of 5 years w.e.f. November 17, 2017 and are not eligible to retire by rotation.

13. Non-Resident Indian members are requested to inform RTA/ respective DP's, immediately of:
 - a) Change in their residential status on return to India for permanent settlement.
 - b) Particulars of their bank account maintained in India with complete name, branch, account type, account number, IFSC Code and address of the bank with pin code number, if not furnished earlier
14. The voting rights of shareholders shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date i.e. Tuesday, 22nd day of September, 2020. Members are eligible to cast vote only if they are holding shares as on that date and a person who is not a member as on the cut-off date should treat this notice for information purposes only.
15. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories and Company's RTA as on the cut-off date only shall be entitled to avail the facility of voting at the AGM through VC/OAVM.
16. In terms of Section 152 of the Act, Ms. Meenakshi Gupta, is liable to retire by rotation at this Annual General Meeting and being eligible, offers herself for re-appointment.
17. Mr. Hitesh Patel, Non-Executive Director, has been appointed as per the provisions of the Companies Act, 2013 for a period of 1 year with effect from 5th September, 2020, liable to retire by rotation.
18. **ELECTRONIC DISPATCH OF ANNUAL REPORT AND PROCESS FOR REGISTRATION OF EMAIL ID FOR OBTAINING COPY OF ELECTRONIC ANNUAL REPORT:**
 1. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM/EGM has been uploaded on the website of the Company at (www.deccanhealthcare.co.in). The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com respectively. The AGM Notice is also disseminated on the website of CDSL (agency for providing the voting system during the AGM) i.e. www.evotingindia.com.
19. **PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL ADDRESSES ARE NOT REGISTERED WITH THE DEPOSITORIES FOR OBTAINING LOGIN CREDENTIALS FOR E-VOTING FOR THE RESOLUTIONS PROPOSED IN THIS NOTICE:**
 1. For Demat shareholders, please provide Demat account details (CDSL-16 digit beneficiary ID or NSDL-16 digit DPID + CLID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to Company/RTA email id.
20. **INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE EGM THROUGH VC/OAVM ARE AS UNDER:**
 1. Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL e-Voting system. Shareholders may access the same at

<https://www.evotingindia.com> under shareholders/members login by following the procedure written in point No. 19. The link for VC/OAVM will be available in shareholder/members login where the EVSN of Company will be displayed.

2. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
3. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast **7 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **7 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.
6. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

21. INSTRUCTIONS FOR SHAREHOLDERS FOR E-VOTING DURING THE AGM ARE AS UNDER:-

1. The shareholders should log on to the e-voting website www.evotingindia.com.
2. Click on "Shareholders" module.
3. Now enter your User ID

- a. For CDSL: 16 digits beneficiary ID,
- b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,

OR

Alternatively, if you are registered for CDSL's EASI/EASIEST e-services, you can log-in at <https://www.cdslindia.com> from Login - Myeasi using your login credentials. Once you successfully log-in to CDSL's EASI/EASIEST e-services, click on e-Voting option and proceed directly to cast your vote electronically.

4. Next enter the Image Verification as displayed and Click on Login.
5. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

6. If you are a first time user follow the steps given below:

For Shareholders holding shares in Demat Form and Physical Form	
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).

7. After entering these details appropriately, click on “SUBMIT” tab.

8. Shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

9. For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

10. Click on the EVSN for the relevant <Company Name> on which you choose to vote.

11. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

12. Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.

13. After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.

14. Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
15. You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
16. If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
17. Shareholders can also cast their vote using CDSL’s mobile app “m-Voting”. The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.
18. Only those shareholders, who are present in the EGM/AGM through VC/OAVM facility and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
19. If any Votes are cast by the shareholders through the e-voting available during the EGM/AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility , then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

22. Note for Non – Individual Shareholders and Custodians

1. Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
2. A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
3. After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
4. The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
5. A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
6. Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the

Company at the email address viz; investors@deccanhealthcare.co.in (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

If you have any queries or issues regarding attending AGM & e-Voting from the e-Voting System, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com or contact Mr. Nitin Kunder (022- 23058738) or Mr. Mehboob Lakhani (022-23058543) or Mr. Rakesh Dalvi (022-23058542).

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

23. **DECLARATION OF RESULTS:**

1. Ms. Monika Bhatia, a Practicing Company Secretary (Membership No. FCS 10397), M/s. M. R. Bhatia & Co, has been appointed as the Scrutinizer to scrutinize the voting process in a fair and transparent manner.
2. The Scrutinizer shall after the conclusion of voting at the AGM, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than 48 hours of the conclusion of the AGM, a consolidated scrutinizer’s report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith. The results shall be declared not later than forty-eight hours from conclusion of the meeting by posting the same on the website of the Company (www.deccanhealthcare.co.in), website of CDSL (www.evotingindia.com) and by filing with BSE Ltd and It shall also be displayed on the Notice Board at the Registered Office of the Company. Subject to receipt of requisite number of votes, the Resolution shall be deemed to be passed on the date of the Meeting i.e. 29th September, 2020

EXPLANATORY STATEMENT
Pursuant to section 102 of the Companies Act 2013

Item: 4:-

Your Directors propose to alter the Articles of Association (AOA) of the Company to enable the Members of the Company including Promoters & Promoters Group, who hold the equity shares in the Company to waive/forgo his/her/their right to receive the dividend, interim or final, by him/her/them for any financial year which may be declared or recommended respectively by the Board of Directors of the Company or Members of the Company.

Now, Pursuant to provision of section 14 of the Companies Act, 2013, for the Alteration of Articles of Association of the Company, Members approval is required by way of passing of Special Resolution.

Hence, the Resolution as at Item No. 4 of the Notice is therefore set out as a Special Resolution for approval of the Members. None of the Directors and/or Key Managerial Personnel [KMP] of the Company and their relatives are concerned or interested in the resolution set out at Item no. 4 except to the extent of Shareholding in the Company.

Place: Hyderabad
Date: 05.09.2020

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Sd/-
Sheena Jain
Company Secretary
(ACS: 52795)

ANNEXURE – I

Details of Director's eligible for appointment/re-appointment pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards-2 (SS-2).

Name of Director	Meenakshi Gupta	Hitesh Mohanlal Patel
Category of Directorship	Whole time Director	Non-Executive Director
DIN	00574624	02080625
Date of Birth	26 th March, 1960	14 th June, 1975
Age	60 years	45 years
Date of Appointment on the Board	30.05.2019	30.05.2019
Qualification	She holds Master Degree in Science from Maharaja Sayajirao University of Baroda	Higher Secondary examination from Maharashtra Board
Experience	Meenakshi Gupta, aged 58 years is the Whole Time Director of our Company. She was appointed as Additional Director of our company on October 29, 2014. She holds Master Degree in Science from Maharaja Sayajirao University of Baroda. She is responsible for corporate development, training & education and Human Resource management.	Hitesh Patel, aged 43 years is the Promoter and Non - Executive Director of our Company. He has passed his Higher Secondary examination from Maharashtra Board. He is the guiding force behind all the strategic decisions. He plays a key role in developing macro investment themes, understanding strengths and weaknesses of specific companies, and indentifying superior management teams. Post investment, he provides key strategic inputs on strengthening the business model of portfolio companies. He brings a very unique perspective of understanding the value drivers across industries and at the same time has a first-hand understanding of the challenges faced by small to mid-size companies as they scale their businesses
No. of other Directorships in public Ltd Companies	Nil	1. Nutricircle Limited
Chairman/Member of the Committees of the Board of Directors of the Company.#	Nil	2
Audit Committees	Nil	Member, Nutricircle Limited

Stakeholders Relationship Committee	Nil	Member, Nutricircle Limited
No of Equity Shares held in the Company	1707333	3009214
Number of Board Meetings attended during the year	5/7	5/7
Terms and conditions of appointment/ re-appointment	Whole time Director, liable to retire by rotation	Whole time Director, liable to retire by rotation
Remuneration sought to be paid and the remuneration last drawn	See Note given below##	See Note given below
Relationship with Other Directors, Manager and Key Managerial Personnel	Ms. Meenakshi Gupta is Wife of Mr. Minto Purshotam Gupta, Managing Director of Deccan Health Care Limited	No relationship with other Director, Manager and Key Managerial Personnel.
Justification for choosing the Independent Director	NA	NA

#Audit Committee and Stakeholders Relationship Committee have been considered.

Note: The Non-Executive Directors (including Independent Directors) are paid sitting fee for attending meetings of Board of Directors, Independent Directors and various Committee of Directors.

shareholder's at 23rd Annual General Meeting of the Company have approved the Remuneration of Ms. Meenakshi Gupta pursuant to Section 197 the Companies Act 2013, for the period of three(3) Years starting from 31st August, 2020.

DIRECTORS' REPORT

To
The Members of
Deccan Health Care Limited

Your Directors have pleasure in presenting their 24th Annual Report on the business and operations of the Company and the Audited Financial Statements for the financial year ended March 31, 2020.

Financial Summary or Highlights/Performance

(Rs. in Lakhs except EPS)

Particulars	For the Year ended 31 st March, 2020	For the Year ended 31 st March, 2019
Revenue from Operations	4,224.41	4,424.79
Other Income	5.72	8.40
Total Revenue	4,230.13	4,433.19
Expenses :		
Cost of Material Consumed	2,338.65	1,935.48
Changes in Inventories of Finished Goods and Work-in-Progress	(663.78)	(421.48)
Employee Benefit Expenses	433.38	409.22
Other Expenses	948.65	821.08
Finance Cost	18.32	103.57
Depreciation and Amortization Expenses	141.73	128.64
Total Expenses	3,216.95	2,976.51
Profit / (Loss) Before Tax	1,013.18	1,456.68
Tax Expenses :		
Provision for Income Tax (MAT)	177.02	313.97
Less : MAT Credit Entitlement	(177.02)	(313.97)
Deferred Tax	4.44	8.63
Profit / (Loss) for the period	1,008.74	1,448.05
Earnings Per Share :		
Basic	6.42	10.29
Diluted	6.42	10.29

Performance at a glance

The Company recorded net sales of 4230.13 Lakhs during the financial year 2019-20 as compared to 4433.19 Lakhs in the previous financial year. The Net Profit during the financial year 2019-20 was at 1008.74 Lakhs as compared to a net profit of 1448.05 Lakhs in financial year 2018-19 translating to Basic Earnings Per Share at 6.42 for the financial year 2019-20 as compared to 10.29 in financial year 2018-19.

Impact of Covid-19

As the company is re-gearing its engines at an unprecedented rate as lockdown rules are gradually relaxed, the challenge is complicated by uncertainties about the progression of COVID-19 and the social, political and fiscal actions that it will drive. There is a rapidly positive trend for the company in terms of market driven demand. The company has been architecting measures within possible means to optimize the circumstances which were and are beyond control ensuring continuity in consumer retention and incepted new consumer acquisition strategy. The company's top priority at these times is to foster market space and consumer share, increase orders on its online portal and build new infrastructure to serve the consumers. This presents us with an opportunity – and a need – to enhance the competences: to be more digital, data-driven, and in the cloud; to new consumer share in the market, agile operations and automation; to create stronger capabilities in e-commerce. This agility will be core to the long-term capabilities we build. The company examined the implications for operations and supply chain. The COVID-19 pandemic has brought fast-moving and unexpected variables. The Company has developed management plans specific to this crisis briefly discussed below, for a positive immediate and long-term result.

Dividend

In view of the future expansion plans, Board of Directors have not recommended any dividend for the financial year ended 31st March, 2020.

Change in Share Capital

During the Financial Year 2019-20, there was no change in the Share Capital of the Company.

Change in the Nature of Business

There is no change in the nature of business during the financial year 2019-20.

Material Changes and Commitments

No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

Management Discussion and Analysis

Management Discussion and Analysis Report as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Annual Report.

Directors and Key Managerial Personnel

The following is the Composition of the Board of Director's as on 31st March, 2020

Name of the Director	Category
Mr. Minto Purshotam Gupta	Managing Director (Promotor)
Ms. Meenakshi Gupta	Executive Director (Promotor)
Mr. Hitesh Patel	Non-executive Director (Promotor)
Mr. Narendra Singh	Independent Director
Ms. Savita Bhutani	Independent Director (women Director)

Mr. Yezdi Jal Batliwala (DIN 03018605) resigned from the Directorship of the Company w.e.f. 07.03.2020 due to his personal reasons.

Ms. Meenakshi Gupta (DIN 00574624) shall retire by rotation at the ensuing Annual General Meeting and being eligible, offer herself for re-appointment. The Board hereby recommends her re-appointment for approval of shareholders in the ensuing Annual General Meeting.

Mr. Hitesh Patel (DIN 02080625) was re-appointed by the Board of Directors of the Company, on the recommendation of the Nomination and Remuneration Committee at their meeting held on 05th September, 2020, as a Non-Executive Director of the Company liable to retire by rotation, to hold office for a term of one year effective 05th September, 2020. Board have recommends his appointment for approval of shareholders in the ensuing Annual General Meeting.

Pursuant to Section 149 (10) of the Act, read along with the Rules framed thereunder, the Members had at the 22nd Annual General Meeting (AGM) of the Company held on 20th September, 2018, approved the appointment of Independent Directors (viz Mr. Narendra Singh and Mrs. Savita Bhutani) for the period of 5 (five) years w.e.f. 17th November, 2017.

Mr. Minto Purshotam Gupta was reappointed as Managing Director of the Company for the period of 3 (three) years, w.e.f. 31st August, 2019 by the members of the Company at the 23rd Annual General Meeting (AGM) held on 30th September, 2019.

Key Managerial Personnel

1. Mr. Uttam Kumar Singh, Chief Financial Officer*
2. Ms. Sreya Mitra, Company Secretary**

3. Ms. Sheena Jain, Company Secretary#

Note:

*Mr. Uttam Kumar Singh has resigned from the services of Chief Financial Officer of the Company w.e.f. 19th August, 2020.

**Ms. Sreya Mitra has resigned from the post of Company Secretary w.e.f. 19th October, 2019.

#Ms. Sheena Jain was appointed as Company Secretary w.e.f. 14th November, 2019.

Remuneration of Directors, Key Managerial Personnel & Particulars of Employees

The information required under Section 197 of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms an integral part of this Report is attached as Annexure - I.

The statement containing particulars of employees as required under section 197 of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, will be provided upon request. In terms of Section 136 of the Companies Act, 2013, the Report and accounts are being sent to the members and others entitled thereto.

Board Meetings

During the year under review, Seven (7) Board Meetings were held, the dates being, 30th May, 2019, 23rd July, 2019, 30th September, 2019, 14th November, 2019, 24th December, 2019, 23rd January, 2020 and 10th February, 2020.

The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

Attendance at the Last AGM of the Company held on 30th September, 2019:

Name of Director	Attendance at the last AGM held on 30 th September, 2019
Minto Purshotam Gupta	Yes
Meenakshi Gupta	Yes
Yezdi Jal Batliwala*	No
Hitesh Patel	Yes
Narendra Singh	No
Savita Bhutani	No

Declaration by Independent Directors

Mr. Narendra Singh and Mrs. Savita Bhutani are the Independent Directors on the Board of your Company. In the opinion of the Board and as confirmed by these Directors, they fulfil the conditions specified in Section 149(6) of the Act and the Rules made thereunder about their status as Independent Directors of the Company.

Performance Evaluation

In compliance with the Companies Act, 2013, and the Listing Regulations, the Board has carried out the annual performance evaluation of the Directors individually as well as evaluation of the working of the Board and the committees of the Board, by way of individual and collective feedback from the Directors.

The following were the Evaluation Criteria:

(a) For Independent Directors:

- Knowledge and Skills
- Professional conduct
- Duties, Role and functions

(b) For Executive Director:

- Performance as Team Leader/Member
- Evaluating Business Opportunity and analysis of Risk Reward Scenarios
- Key Set Goals and Achievements
- Professional Conduct and Integrity

- Sharing of Information with the Board

The Directors expressed their satisfaction with the evaluation process.

Board Committees

During the year under review, the Board of Directors of your Company had constituted and re-constituted various Committees and approved the terms of reference / role in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015 viz. Following are the Committees of Board and its Members as at the financial year end date i.e. 31-03-2020.

Committees	Name of Director	Designation
1. Audit Committee	Narendra Singh	Chairman
	Hitesh Patel	Member
	Savita Bhutani	Member

During the Financial Year ended 31st March, 2020, the Audit Committee met four (4) times on 30th May, 2019, 23rd July, 2019, 14th November, 2019 and 24th December, 2019 and the requisite quorum was present at the Meeting.

2. Stakeholder Relationship Committee	Narendra Singh	Chairman
	Savita Bhutani	Member
	Hitesh Patel	Member

During the Financial Year ended 31st March, 2020, the Stakeholder Relationship Committee met once (1) on 30th May, 2019 and the requisite quorum was present at the Meeting.

3. Nomination & Remuneration Committee	Savita Bhutani	Chairman
	Narendra Singh	Member
	Hitesh Patel	Member

During the Financial Year ended 31st March, 2020, the Nomination & Remuneration Committee met once (1) on 14th November, 2019 and the requisite quorum was present at the Meeting.

4. Corporate Social Responsibility	Minto Purshotam Gupta	Chairman
	Hitesh Patel	Member
	Yezdi Jal Batliwala*	Member
	Savita Bhutani	Member

During the Financial Year ended 31st March, 2020, the Corporate Social Responsibility Committee met once (1) on 24th December, 2019 and the requisite quorum was present at the Meeting.

*Mr Yezdi Jal Batliwala resigned w.e.f 7th March, 2020, subsequently Ms. Savita Bhutani was appointed as Member of the CSR committee.

Company Secretary act as the Secretary to all the above four constituted Committees.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of reference / role of the Committees are taken by the Board of Directors.

Subsidiary Companies

The Company does not have any subsidiaries, joint ventures or associate companies during the year under the review. Hence, the company does not make any disclosures in form AOC-1 as per the requirements of section 129(3) of the Companies Act, 2013 and rules made thereunder.

However, on 12th May, 2020, Beyoungstore Private Limited, a wholly owned subsidiary of Deccan Health Care Limited was incorporated having Authorised Capital of Rs. 10,00,000 (Rs Ten Lakhs) divided into 100,000 shares of Rs. 10/- each and Paid up Capital of Rs. 100,000 (Rs. One Lakh) divided into 10,000 shares of Rs. 10/- each.

Details about Related Party Transactions

During the period under review, the following is the related party transactions as defined under Section 188 of the Companies Act, 2013 and rules framed thereunder and same were provided in Form AOC-2 forming part of this Annual Report.

Details about Loans, Guarantee & Investment Under Section 186

During the year under review, the Company has complied with the provisions of the Section 186 of the Companies Act, 2013 and rules made thereunder.

Internal Control/ Internal Financial Control Systems and Adequacy Thereof

The Company has aligned its current systems of internal financial control with the requirement of Companies Act, 2013, the framework requires a company to identify and analyze risks and manage appropriate responses. The company has successfully laid down the framework and ensured its effectiveness.

Human Resources

The Company believes that quality of its employees is the key to success in long run. The Company continues to have cordial relations with its employees.

Conservation Of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The information with regard to Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo in accordance with the provisions of Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is given as **Annexure-II** forming part of this Report.

Auditors

a) Statutory Auditor

In the Annual General Meeting (AGM) of the Company held on 30th September, 2019, M/s. Keyur Shah & Co., Chartered Accountants, Ahmedabad, (FRN: 141173W), were appointed as the Statutory Auditors of the Company to hold office as the Statutory Auditors until the conclusion of the 28th Annual General Meeting (AGM) of the Company to be held in the year 2024.

Pursuant to the notification dated 7th May, 2018 issued by Ministry of Corporate Affairs, the requirement for ratification of appointment of Auditors by the shareholders at every Annual General Meeting has been done away with. Further, the Auditors have confirmed their eligibility under section 141 of the Companies Act, 2013 and the rules made thereunder.

Further, the report of the Statutory Auditors along with notes is enclosed to this report. The remarks in the Report are already explained in the Notes to Accounts and as such does not call for any further explanation or elucidation.

No fraud has been reported by the Statutory Auditors under Section 143(12) of the Companies Act, 2013 and the rules made thereunder.

B) Secretarial Audit

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company had appointed M/s. M. R. Bhatia & Co., a firm of Company Secretaries in Practice to undertake the Secretarial Audit of the Company for the Financial Year 2019-20. The Secretarial Audit Report is annexed herewith as **Annexure-III**.

The Secretarial Audit Report does not contain any qualification, reservation or adverse remark. No fraud has been reported by the Secretarial Auditors under Section 143 (12) of the Companies Act, 2013 and the rules made thereunder.

c) Internal Auditor

Company has appointed M/s SLR & Associates, Chartered Accountants, Hyderabad (FRN: 0158745) to oversee and carry out internal audit of its activities for the FY 2020-21

Corporate Social Responsibility (CSR)

The Company takes its social responsibility very seriously and supports the report of governing bodies. This report interprets social responsibility and healthcare delivery as both “passive” and “active” in how to manage internal operations and the impact of activities on the community and environment.

At Deccan Health Care we engage in “passive” social responsibilities by complying with regulatory requirements and general ethical standards, such as:

- respecting human rights;
- non- discriminatory work practices;
- protecting privacy rights that improve society;
- having environmental policies and practices that protect our society and environment

We are also committed to “active” social responsibilities that go beyond legal obligations and general ethical standards. We actively pursue the interests and values of individuals and the local and global community and environment. These ‘moral obligations’ include: actively promoting preventive health education programmes designed to improve the health and quality of life of residents; introducing best practice environmental management.

These all contribute to the common good of people in the workplace, the community and the environment.

Our commitment to diversity and anti-discrimination policies is reflected in the profile of our employees. We have an anti-discrimination policy in place to ensure that there is no discrimination or harassment of any person employed or seeking employment on the basis of their race, colour, religion, gender, age or nationality. In addition, our workforce is nearly equally split between female and male employees. We believe that this widespread cultural and balanced gender mix is testament to our outlook of global expansion.

The Company recognizes the importance and our responsibility of environmental stewardship. Reflecting our role in the sustainable management of India’s environment, we are committed to conducting our work in an environmentally responsible way. We operate in compliance with all relevant environmental legislation and we continue to strive to use pollution prevention and environmental best practices in the workplace to minimise our potential impact on the environment.

The Company has well framed the CSR policy for its effective implementation in the Company and the reporting in respect of the Corporate Social Responsibility is as well annexed to the Board Report for your reference as **Annexure “IV”**

Disclosure as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

The Company has zero tolerance towards sexual harassment at the workplace and has set up Internal Complaints Committee (ICC) for prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. During the year 2019-20, the Company has not received any complaint of sexual harassment.

Credit Rating

During the Financial Year, there was no credit rating being obtained by the Company.

Public Deposits

The Company has not accepted any deposits from the public/members under section 73 of the Companies Act, 2013, read with Companies (Acceptance of Deposits) Rule, 2014 during the year.

Directors' Responsibility Statement

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statements in terms of Section 134 (5) of the Companies Act, 2013;

(a) That in the preparation of the annual accounts, the applicable accounting standards read with requirements set out under Schedule III to the Companies Act, 2013 have been followed along with proper explanation relating to material departures;

(b) That such accounting policies as mentioned in Notes to the Financial Statements have been selected and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2019 and of the profit of the Company for the year ended on that date;

(c) That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) That the annual financial statements have been prepared on a going concern basis;

(e) That proper internal financial controls were in place and that the financial controls were adequate and were operating effectively;

(f) That systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concern Status of the Company

There has been no significant and material Order passed by the Regulators or Courts or Tribunals in the FY 2019-20, impacting the going concern status of the Company's operations.

Extract of Annual Return U/S 92 (3) in MGT-9

As per the provisions of Section 92(3) of the Companies Act, 2013 ('the Act') read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014, the extract of the Annual Return in Form MGT-9 is given in **Annexure "V"**, forming part of this report.

Insider Trading

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (Regulations), your Company has adopted the following:

- i) Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders- The said Code lays down guidelines, which advise Insiders on the procedures to be followed and disclosures to be made in dealing with the shares of the Company and cautions them on consequences of non-compliances.

ii) Code of Practices and Procedures of Fair Disclosures of Unpublished Price Sensitive Information- The Code ensures fair disclosure of events and occurrences that could impact price discovery in the market.

iii) Policy for dealing with Unpublished Price Sensitive Information (UPSI) and Whistle Blower Policy for employees to report any leak or suspected leak of UPSI- The policy aims to enable the employees of the Company to report any leak or suspected leak of UPSI, procedures for inquiry in case of leak of UPSI or suspected leak of UPSI and initiate appropriate action and informing the SEBI promptly of such leaks, inquiries and results of such inquiries.

iv) Internal Control Mechanism to prevent Insider Trading- The Internal Control Mechanism is adopted to ensure compliances with the requirements given in the regulations and to prevent Insider Trading. The Audit Committee reviewed and found the same in order.

Vigil Mechanism

The Company has adopted a Whistle Blower Policy establishing vigil mechanism, to provide a formal mechanism to the Directors and Employees to report their concerns about unethical behaviour, actual or suspected fraud or violation of the Company's Code of Conduct or ethics policy. The Policy provides for adequate safeguards against victimization of employees who avail of the mechanism.

Acknowledgements

Your Directors wish to place on record their appreciation of the contribution made by the employees at all level, towards the continued growth and prosperity of your company. Your Directors also wish to place on record their sincere thanks to the Banks and various Government Authorities for the support and co-operation extended to the Company. Your Directors are especially grateful to the shareholders for reposing their trust and confidence in the Company.

**By order of the Board of
Directors
For DECCAN HEALTH CARE LIMITED**

**Place: Hyderabad
Date: 05.09.2020**

**DR. MINTO P. GUPTA
Managing Director
(DIN 00843784)**

**HITESH PATEL
Director
(DIN 02080625)**

"Annexure – I"
DETAILS OF REMUNERATION OF DIRECTORS, KMPs AND EMPLOYEES
Pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5 of Companies
(Appointment & Remuneration) Rules, 2014

1.	The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2019 -20	Director/KMP Name	Ratio of Remuneration of each Director/ to median Remuneration of employees
		Minto Purshotam Gupta	15.16
		Meenakshi Gupta	10.49

Note:

The aforesaid details are calculated on the basis of the gross remuneration received by the employees for the financial years 2018 -19 & 2019 -20.

2.	The Percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager if any in the Financial Year 2019 -20	Director/KMP Name	% increase in remuneration
		Minto Purshotam Gupta	(15.73)
		Meenakshi Gupta	56.24
		Uttam Kumar Singh	2.22
		Sheena Jain*	Nil
		Sreya Mitra**	Nil
3.	The information of employees receiving salary in excess of the limits as prescribed under the provisions of Section 197 read with Rule 5, sub rule 2 & 3 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and the Companies (Appointment and remuneration of Managerial Personnel) Amendment Rules, 2016 under the Companies Act, 2013, who were employed throughout or for a part of the financial year under review	Nil	
4.	Percentage increase in the median remuneration of employees in the Financial Year 2019 -20	15.21%	
5.	The Average percentile increase in salaries of employees other than managerial personnel in the last financial year and its comparison with the percentage increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration	The average salary of the employees was increased by 5.69%	
6.	Number of permanent employees on the rolls of the Company	59	
7.	Affirmation that the remuneration is as per the Remuneration Policy of the Company	It is hereby affirmed that the remuneration paid during the year is as per the Nomination and Remuneration Policy of the Company	

*Ms. Sheena Jain was appointed on 14th November, 2019

**Ms. Sreya Mitra resigned w.e.f. 19th October, 2019

“ Annexure -II ”

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

A. ENERGY CONSERVATION

Deccan Health Care Limited has always been a frontrunner in continually improving its operational performance in all areas, like productivity, yield, utilization and a host of other operating metrics, while reducing the consumption of fuel, power, stores and others. This is done by adopting an approach of continual improvement of process metrics across all energy consuming facilities.

The Company is continuously putting its efforts to improve Energy Management by way of monitoring energy related parameters on regular basis.

The Company is committed to transform energy conservation into a strategic business goal fully along with the technological sustainable development of Energy Management System. It is putting best endeavor to reduce energy consumption in its operations and activities.

To achieve above objectives the following steps are being undertaken by the Company: -

- ~ Continuously monitoring the energy parameters such as maximum demand, power factor, load factor on regular basis;
- ~ Continuously replacing the inefficient equipment's with latest energy efficient technology & upgradation of equipment's continually;
- ~ Increasing the awareness of energy saving within the organization to avoid the wastage of energy;
- ~ To enhance utilization of Renewable Energy Resources;
- ~ Exploring the feasibility of utilization of Solar Power at plant locations wherever possible;

B. RESEARCH AND DEVELOPMENT (R&D)

Research, Technology and innovation continue to be one of the key focus areas to drive growth. In addition to developing new design, pattern and styles of Company's product, it also works on building new capabilities. To support this, Company avails services of qualified and experienced professionals / consultants.

C. TECHNOLOGY ABSORPTION

The Company develops in-house Technology and is not dependent on any outside Technology/Source.

D. FOREIGN EXCHANGE EARNINGS AND OUTGO

During the financial year under review, there was no foreign exchange earnings and outgo.

Any gains or losses arising on account of exchange difference either on settlement or on transactions is accounted for in the Statement of Profit & Loss.

SECRETARIAL AUDIT REPORT
For the Financial Year ended March 31, 2020

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Deccan Health Care Limited, Hyderabad
(L72200TG1996PLC024351)

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Deccan Health Care Limited** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period ended on March 31, 2020, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the period ended on March 31, 2020 according to the provisions of:

- I. The Companies Act, 2013 ("the Act") and the Rules made thereunder;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;
- III. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not Applicable to the Company during the Audit Period)

V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') to the extent applicable to the Company :-

- a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- d. The Securities and Exchange Board of India (Share based Employee Benefits) Regulations, 2014;
- e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
- f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Not Applicable to the Company during the Audit Period);
- h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (Not Applicable to the Company during the Audit Period)
- i. The Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015;

VI. Other laws applicable specifically to the Company, namely:

- The Environment Protection Act, 1986;
- The Water (Prevention & Control of Pollution) Act, 1974;
- The Air (Prevention & Control of Pollution) Act, 1981;
- The Hazardous Waste (Management, Handling & Transboundary Movement) Rules, 2008;
- Factories Act, 1948;
- Industrial Disputes Act, 1947;
- The Payment of Wages Act, 1948;
- The Employee State Insurance Act, 1948;

- The Employee Provident Fund and Miscellaneous Provision Act, 1952;
- The Payment of Bonus Act, 1965;
- The Payment of Gratuity Act, 1972;
- The Income Tax Act, 1961;
- Contract Labor (Regulation and Abolition) Act, 1970;
- The Industrial Employment (Standing Orders) Act, 1946;
- The Goods and Service Tax Act, 2017;

We have also examined compliance with the applicable clauses of the following:

- i) Secretarial Standards (SS-1 and SS-2) issued by The Institute of Company Secretaries of India; and
- ii) The Listing Agreements entered into by the Company with the BSE Limited (SME Exchange).

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, Listing Agreements etc mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings. Except where consent of the directors was received for scheduling meeting at a Shorter Notice, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings were carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committees of the Board, as the case may be.

The Company has obtained all necessary approvals under the various provisions of the Act; and there was no prosecution initiated and no fines or penalties were imposed during the year under review under the Act, SEBI Act, SCRA, Depositories Act, Listing Agreement and Rules, Regulations and Guidelines framed under these Acts against / on the Company, its Directors and Officers.

We further report that compliance of applicable financial laws including Direct and Indirect Tax laws by the Company has not been reviewed in the Audit since the same has been subject to review by the Statutory Auditors and other designated professionals.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**For M. R. Bhatia & Co.
Practicing Company Secretaries**

**Monika R. Bhatia
Company Secretary
Proprietor
M. No. 10397
C.P. No.13348
UDIN: F010397B000667009**

**Place: Ahmedabad
Date: 05th Sept 2020**

Note: This report is to be read with our letter of even date which is annexed as "ANNEXURE A" and forms an integral part of this report.

“ANNEXURE A”

To,
The Members,
Deccan Health Care Limited, Hyderabad
(L72200TG1996PLC024351)

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in Secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. We have obtained the Management representation about compliance of laws, rules and regulations and happenings of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of efficacy or effectiveness with which the management has conducted the affairs of the Company.

7. Due to COVID-19 outbreak and Lockdown situation, this Report has been issued relying on the certificate, information, details, data, documents and explanation provided by the Company and its officers, agents and authorized representatives and Registrar and Transfer Agent in electronic form, without physically verifying at their office.

**For M. R. Bhatia & Co.
Practicing Company Secretaries**

**Monika R. Bhatia
Company Secretary
Proprietor
M. No. 10397
C.P. No.13348
UDIN: F010397B000667009**

**Place: Ahmedabad
Date: 05th Sept 2020**

"Annexure -IV "

REPORTING OF CORPORATE SOCIAL RESPONSIBILITY (CSR)

Pursuant to of Section 134(3)(o) of the Companies Act 2013, and Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014

1.	A brief outline of the Company's CSR Policy, including overview of projects or programmes proposed to be undertaken and a reference to the web link to the CSR Policy and projects or programmes.	<p>The Company has framed a Policy in compliance with the provisions of Companies Act, 2013.</p> <p>The Policy encompasses the Company's philosophy of "Serving Society through Industry" and is designed to employ Company's resources, strengths and strategies in discharging its responsibility as a Corporate Citizen.</p> <p>The Company continues to strive to transform the business environment in which it operates. It also works for the transformation of the Society. The aim of the Company is to create an environment which enhances opportunities for all the good things, better education, healthy lives and overall quality of living that life has to offer. The Company designs its CSR initiatives in alignment with its objective of enhancing the quality of life in all aspects.</p>
2.	Composition of the CSR Committee	<p>Dr. Minto P. Gupta - Chairman</p> <p>Mr. Hitesh Mohanbhai Patel - Member</p> <p>Mr. Yezdi Jal Batliwal* - Member</p> <p>Ms. Savita Bhutani - Member</p>
3.	Average net profit of the Company for last three financial years	Rs. 1268.12 Lakhs
4.	Prescribed CSR Expenditure (two percent of amount as in item 3 above)	25.36 Lakhs
5.	<p>Details of CSR spent for the financial year:</p> <p>a) Total amount spent for the financial year</p> <p>b) Amount unspent, if any</p>	<p>NIL</p> <p>Rs. 25.36 Lakhs</p>
6.	In case the Company has failed to spend the 2% of the average net profit of the last three financial years or any part thereof, reasons for not spending the amount	As the Company is yet to finalise its CSR projects, the Company did not incur any expenditure on any CSR activities during the financial year 2019 -20.
7.	Responsibility Statement	The Chairperson of the CSR Committee confirms that the implementation and monitoring of the CSR Policy, is in compliance with the CSR Objectives and Policy of the Company

*Mr. Yedi Jal Batliwala resigned w.e.f. 7th March, 2020

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Place: Hyderabad
Date: 05.09.2020

DR. MINTO P. GUPTA
Managing Director (DIN 00843784)

“Annexure-V”
FORM NO. MGT-9
EXTRACT OF ANNUAL RETURN
as on the Financial Year ended on 31.03.2020

[Pursuant to section 92(3) of the Companies Act, 2013 and
Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:	
i	CIN L72200TG1996PLC024351
ii	Registration Date 14 th June, 1996
iii	Name of the Company DECCAN HEALTH CARE LIMITED
iv	Category / Sub-Category of the Company Public Company – Limited by Shares
v	Address of the Registered office and contact details 247, 2 nd Floor, Dwarkapuri Colony, Punjagutta, Hyderabad, Telangana- 500082, India. E-mail: mailto@deccanhealthcare.co.in ; Contact: 040-40144508; Website: www.deccanhealthcare.co.in
vi	Whether listed company Yes
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any Big Share Services Private Limited 1st Floor, Bharat Tin Works Building, Opposite Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai- 400059 Tel No : +91 22 62638200; Fax No. : +91 22 62638299

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the Company
1	Manufacture of Fast Moving Consumer Health Products (FMCHP)	21003	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S. No.	Name and address of the company	CIN/GLN	Holding/Subsidiary/Associate Company	% of shares held	Applicable section
1	-	-	-	-	-

2. Non-Institutions										
a) Bodies Corporate	2014849	0	2014849	12.82	1950400	0	1950400	12.41		(0.41)
b) Individuals										
i) (Capital upto Rs. 1 Lakhs)	1293583	0	1293583	8.23	1026735	0	1026735	6.53		(1.70)
ii) (Capital Greater than Rs. 1 Lakhs)	3917983	0	3917983	24.93	4845416	0	4845416	30.83		5.90
c) Any Others (specify)										
i) Trusts	0	0	0	0	0	0	0	0		0
ii) Clearing Member	395001	0	395001	2.51	331070	0	331070	2.51		(2.51)
iii) Non Resident Indians	17400	0	17400	0.11	7800	0	7800	0.05		(0.06)
iv) Directors Relatives	0	0	0	0	0	0	0	0		0
v) Employee	0	0	0	0	0	0	0	0		0
vi) Overseas Bodies Corporates	0	0	0	0	0	0	0	0		0
vii) Unclaimed Suspense Account	0	0	0	0	0	0	0	0		0
viii) IEPF	0	0	0	0	0	0	0	0		0
ix) HUF					384995	0	384995	2.45		2.45
d) Qualified Foreign Investor	0	0	0	0	0	0	0	0		0
Sub-total (B)(2):-	7638816	0	7638816	48.61	8546416	0	8546416	54.39		5.78
Total Public Shareholding (B)=(1)+(B)(2)	7638816	0	7638816	48.61	8546416	0	8546416	54.39		5.78
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0		0
Grand Total (A+B+C)	15713430	0	15713430	100	15713430	0	15713430	100		0

ii) Shareholding of Promoters

Sl. No	Name	Shareholding at the beginning of the year (1.04.2019)			Share holding at the end of the year (31.03.2020)			% change In shareholding during the year
		No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1	Vipul M Patel	120000	0.8888	0.0000	134400	0.8553	0.0000	-0.0335
2	Bhavna Hitesh Patel	200000	1.4813	0.0000	200000	1.2728	0.0000	-0.2085
3	Meenakshi Gupta	1707333	12.6456	0.0000	1707333	10.8654	0.0000	-1.7802
4	Deccan Health Care Limited-Ofis Account-Operated By Bigshare Services Pvt Ltd	2000000	14.8132	0.0000	0	0.0000	0.0000	-14.8132

5	Dr. Minto P. Gupta	2107667	15.6107	0.0000	2107667	13.4132	0.0000	-2.1975
6	Hitesh Mohanbhai Patel	3925214	29.0726	0.0000	3925214	24.9800	0.0000	-4.0926
	TOTAL	10060214	74.5122	0.0000	8074614	51.3867	0.0000	-23.1255

(iii) Change in Promoters' Shareholding (please specify, if there is no change):

Sl. No	Name	Shareholding		Increase/Decrease in Shareholding	Cumulative Shareholding during the year	
		No. of Shares At the Beginning (01.04.2019/ end of year 31.03.2020)	% total Shares of the Company		No of Shares	% total Shares of the Company
1	Hitesh Mohanlal Patel	3925214	24.98	(916000)	3009214	19.15
2	Dr. Minto P. Gupta	2107667	13.41	0	2107667	13.41
3	Meenakshi Gupta	1707333	10.8712.65	0	1707333	10.87
4	Bhavna Hitesh Patel	200000	1.271.48	0	200000	1.27
5	Vipul M Patel	134400	0.86	8400	142800	0.91
TOTAL		8074614	51.39	(907600)	7167014	45.61

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No	Name	Shareholding	% total Shares of the Company	Date	Increase/Decrease in Shareholding	Reason	Cumulative Shareholding during the year	% total Shares of the Company
1	KENT RO SYSTEMS LIMITED	968800	6.17	01-04-2019				
		968800	6.17	31-03-2020				
2	DIKSHA GREENS LIMITED	0	0	01-04-2019				
			1.27	31-01-2020	200000	TRANSFER	200000	1.27
			3.47	28-02-2020	346000	TRANSFER	546000	3.47
		546000	3.47	31-03-2020				
3	VALUEWORTH CAPITAL MANAGEMENT PVT LTD	837400	5.33	01-04-2019				
			4.08	31-05-2019	-196400	TRANSFER	641000	4.08

			5.05	07-06-2019	153200	TRANSFER	794200	5.05
			4.98	21-06-2019	-12000	TRANSFER	782200	4.98
			4.34	28-06-2019	-100000	TRANSFER	682200	4.34
			4.99	06-09-2019	101200	TRANSFER	783400	4.99
			4.96	13-09-2019	-3600	TRANSFER	779800	4.96
			4.95	20-09-2019	-2400	TRANSFER	777400	4.95
			4.93	27-09-2019	-2400	TRANSFER	775000	4.93
			4.84	04-10-2019	-14400	TRANSFER	760600	4.84
			4.82	18-10-2019	-3600	TRANSFER	757000	4.82
			4.77	25-10-2019	-7200	TRANSFER	749800	4.77
			4.75	01-11-2019	-3600	TRANSFER	746200	4.75
			4.73	08-11-2019	-2400	TRANSFER	743800	4.73
			4.71	15-11-2019	-3600	TRANSFER	740200	4.71
			4.7	22-11-2019	-2400	TRANSFER	737800	4.70
			4.68	29-11-2019	-2400	TRANSFER	735400	4.68
			4.66	06-12-2019	-3600	TRANSFER	731800	4.66
			4.63	20-12-2019	-3600	TRANSFER	728200	4.63
			4.62	27-12-2019	-2400	TRANSFER	725800	4.62
			4.59	03-01-2020	-4800	TRANSFER	721000	4.59
			4.57	10-01-2020	-3600	TRANSFER	717400	4.57
			4.55	17-01-2020	-2400	TRANSFER	715000	4.55
			3.41	24-01-2020	-178600	TRANSFER	536400	3.41
			3.35	31-01-2020	-9600	TRANSFER	526800	3.35
			3.32	07-02-2020	-4800	TRANSFER	522000	3.32
			3.28	14-02-2020	-7200	TRANSFER	514800	3.28
			3.22	21-02-2020	-8400	TRANSFER	506400	3.22
			3.10	28-02-2020	-19200	TRANSFER	487200	3.10
			2.78	06-03-2020	-50400	TRANSFER	436800	2.78
			2.64	20-03-2020	-21600	TRANSFER	415200	2.64
			2.48	27-03-2020	-25200	TRANSFER	390000	2.48
		390000	2.48	31-03-2020				
4	SMITA ASHVIN SHAH	245000	1.56	01-04-2019				
			1.57	19-07-2019	2400	TRANSFER	247400	1.57
			1.58	26-07-2019	1200	TRANSFER	248600	1.58
			1.57	09-08-2019	-1200	TRANSFER	247400	1.57
			1.58	16-08-2019	1200	TRANSFER	248600	1.58
			1.59	23-08-2019	1200	TRANSFER	249800	1.59
			1.58	30-08-2019	-1200	TRANSFER	248600	1.58

		164400	1.05	31-03-2020					
	PANTOMATH STOCK BROKERS								
10	PRIVATE LIMITED	232800	1.48	01-04-2019					
			1.51	05-04-2019	4800	TRANSFER	237600	1.51	
			1.53	12-04-2019	2400	TRANSFER	240000	1.53	
			1.5	19-04-2019	-4800	TRANSFER	235200	1.50	
			1.53	19-04-2019	4800	TRANSFER	240000	1.53	
			1.69	26-04-2019	25200	TRANSFER	265200	1.69	
			1.53	26-04-2019	-25200	TRANSFER	240000	1.53	
			1.53	10-05-2019	1200	TRANSFER	241200	1.53	
			1.53	17-05-2019	-1200	TRANSFER	240000	1.53	
			1.51	31-05-2019	-2400	TRANSFER	237600	1.51	
			1.52	07-06-2019	1200	TRANSFER	238800	1.52	
			1.50	14-06-2019	-2400	TRANSFER	236400	1.50	
			1.28	28-06-2019	-36000	TRANSFER	200400	1.28	
			2.16	05-07-2019	139200	TRANSFER	339600	2.16	
			1.52	19-07-2019	-100000	TRANSFER	239600	1.52	
			2.08	19-07-2019	86800	TRANSFER	326400	2.08	
			2.15	26-07-2019	11600	TRANSFER	338000	2.15	
			2.02	26-07-2019	-20000	TRANSFER	318000	2.02	
			2.16	02-08-2019	20800	TRANSFER	338800	2.16	
			1.9	02-08-2019	-40000	TRANSFER	298800	1.90	
			1.92	09-08-2019	2400	TRANSFER	301200	1.92	
			1.73	09-08-2019	-30000	TRANSFER	271200	1.73	
			1.84	16-08-2019	18000	TRANSFER	289200	1.84	
			1.94	23-08-2019	15600	TRANSFER	304800	1.94	
			1.83	23-08-2019	-18000	TRANSFER	286800	1.83	
			2.04	30-08-2019	33600	TRANSFER	320400	2.04	
			1.81	30-08-2019	-36000	TRANSFER	284400	1.81	
			1.83	06-09-2019	2600	TRANSFER	287000	1.83	
			1.79	06-09-2019	-5000	TRANSFER	282000	1.79	
			1.83	13-09-2019	5600	TRANSFER	287600	1.83	
			1.70	13-09-2019	-21200	TRANSFER	266400	1.70	
			1.73	20-09-2019	4800	TRANSFER	271200	1.73	
			1.72	20-09-2019	-1200	TRANSFER	270000	1.72	
			1.67	27-09-2019	-7200	TRANSFER	262800	1.67	
			1.69	04-10-2019	2400	TRANSFER	265200	1.69	
			1.66	04-10-2019	-3600	TRANSFER	261600	1.66	

				0.05	09-08-2019	-10800	TRANSFER	8400	0.05
				0.06	16-08-2019	1200	TRANSFER	9600	0.06
				0.05	23-08-2019	-2400	TRANSFER	7200	0.05
				0.00	06-09-2019	-7200	TRANSFER	0	0.00
				0.02	15-11-2019	2400	TRANSFER	2400	0.02
				0.00	22-11-2019	-2400	TRANSFER	0	0.00
				0.03	03-01-2020	4800	TRANSFER	4800	0.03
				0.02	10-01-2020	-1200	TRANSFER	3600	0.02
				0.03	17-01-2020	1200	TRANSFER	4800	0.03
				0.10	31-01-2020	10800	TRANSFER	15600	0.10
				0.13	14-02-2020	4800	TRANSFER	20400	0.13
				0.18	21-02-2020	7200	TRANSFER	27600	0.18
				0.18	20-03-2020	1200	TRANSFER	28800	0.18
				0.21	27-03-2020	4800	TRANSFER	33600	0.21
				0.21	31-03-2020				
12	GITA KIRTI AMBANI		196600	1.25	01-04-2019				
			196600	1.25	31-03-2020				
13	SANJAY JAISWAL		187200	1.19	01-04-2019				
				1.19	09-08-2019	4800	TRANSFER	192000	1.22
			192000	1.22	31-03-2020				
14	JAYESH CHANDRAKANT SHAH		150000	0.95	01-04-2019				
			150000	0.95	31-03-2020				

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	For each of the Directors and KMP	Shareholding at the beginning of the year 1-04-2019		Increase/ Decrease in shareholding if any	Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company		No. of shares	% of total Shares of the company
1	Dr. Minto P. Gupta (Director and KMP)	2107667	13.41	-	2107667	13.41
2	Meenakshi Gupta (Director)	1707333	10.87	-	1707333	10.87
3	Hitesh Mohanbhai Patel (Director)	3925214	24.98	(916000)	3009214	19.15
4	Yezdi Jal Batiwal	100000	0.64	-	100000	0.64

	(Director)						
5	Narendra Singh (Director)	0	0	-	0	0	0
6	Savita Bhutani (Director)	0	0	-	0	0	0
7	Uttam Kumar Singh (KMP)	0	0	-	0	0	0
8	Sreya Mitra* (KMP)	0	0	-	0	0	0
9	Sheena Jain** (KMP)	0	0	-	0	0	0

*Ms. Sreya Mitra has resigned from the post of Company Secretary w.e.f. 19th October, 2019.

**Ms. Sheena Jain was appointed as Company Secretary w.e.f. 14th November, 2019.

VI. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment:

		(Rs. in Lakhs)				
		Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness	
Indebtedness at the beginning of the financial year						
i)	Principal Amount	118.00	170.56	0	288.56	
ii)	Interest due but not paid	0	0	0	0	
iii)	Interest accrued but not due	0	0	0	0	
Total (i+ii+iii)		118.00	170.56	0	288.56	
Change in Indebtedness during the financial year						
•	Addition	37.44	0	0	37.44	
•	Reduction	48.75	147.81	0	196.56	
Net Change		(11.31)	(147.81)	0	(159.12)	
Indebtedness at the end of the financial year						

i) Principal Amount	106.69	22.75	0	129.44
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	106.69	22.75	0	129.44

VII. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

A. Remuneration to Chairman, Managing Director & Whole-time Directors:

SN.	Particulars of Remuneration	Name of WTD/MD/Manager (Amount in Lakhs.)		
		Dr. Minto P. Gupta MD	Meenakshi Gupta WTD	
1	Gross salary (Rs. in Lakh)	65.50	45.31	
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	0	0	
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0	0	
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	0	0	
2	Stock Option	0	0	
3	Sweat Equity	0	0	
4	Commission - as % of profit - others, specify ...	0	0	
5	Others, please specify	0	0	
	Total (A)	65.50	45.31	
	Ceiling as per the Act (Rs. in Lakh)	Remuneration is being paid in accordance with Section 197 read with Schedule V of the Companies Act, 2013.		

B. REMUNERATION TO OTHER DIRECTORS

SN.	Particulars of Remuneration	Name of Director (Rs. in Lakh)		
		Yezdi Jal Batliwala	Narendra Singh	Savita Bhutani
1	Independent Directors			Hitesh M Patel
	Fee for attending board/committee meetings	0	0	0.25
	Commission	0	0	0

	Others, please specify	0	0	0	0	0	
	Professional Fees	0	0	0	0	0	
	Total (1)	0	0	0	0.25	0	
2	Other Non-Executive Directors						
	Fee for attending board/committee meetings	0	0	0	0	0	
	Commission	0	0	0	0	0	
	Others, please specify	0	0	0	0	0	
	Total (2)	0	0	0	0	0	
	Total (B)=(1+2)	0	0	0	0.25	0	
	Overall Ceiling as per the Act (Rs. in Lakh)	Ceiling of Rs. 1,00,000/- (Rupees One lakh only) sitting fees per meeting as per the Companies Act, 2013.					

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL (OTHER THAN MD/MANAGER/WTD)

SN	Particulars of Remuneration	Key Managerial Personnel(Amount in Lakhs)		
		Mr. Uttam Kumar singh(Chief Financial Officer)	Ms. Sreya Mitra* (Company Secretary)	Ms. Sheena Jain* (Company Secretary)
1	Gross salary (Rs. in Lakh)	11.95	3.83	3.95
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	0	0	0
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0	0	0
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	0	0	0
2	Stock Option	0	0	0
3	Sweat Equity	0	0	0
4	Commission	0	0	0
	- as % of profit	0	0	0
	others, specify...	0	0	0
5	Others, please specify	0	0	0
	Total	11.95	3.83	3.95

*Ms. Sreya Mitra has resigned from the post of Company Secretary w.e.f. 19th October, 2019.

**Ms. Sheena Jain was appointed as Company Secretary w.e.f. 14th November, 2019.

VIII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY			NIL		
Penalty					
Punishment					
Compounding					
B. DIRECTORS			NIL		

Penalty							
Punishment							
Compounding							
C. OTHER OFFICERS IN DEFAULT							
Penalty							
Punishment							
Compounding							

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Place: Hyderabad
Date: 05.09.2020

DR. MINTO P. GUPTA
Managing Director (DIN 00843784)

HITESH PATEL
Director (DIN 02080625)

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Industry Structure and Developments

According to IMARC, the global nutraceuticals market reached \$266 billion in 2018, registering a CAGR of 6% during 2011-2018. Nutraceuticals are products that provide additional nutrition and health advantages to the human body. As nutraceuticals augment the immune and digestive systems and improve the cognitive behaviour of consumers, their demand is being encouraged at a global level. Increasing awareness around the consumption of healthy foods, shift from chemically derived products to protective healthcare items, steady innovation of natural ingredients used in nutraceuticals and faster growth of e-commerce are some factors driving nutraceuticals demand worldwide. Further, the industry has attained maturity in developed economies like the US. As a result, international manufacturers are now diversifying their businesses to developing regions to expand their consumer base. This shift is further being simplified by rapid urbanisation, increasing western influence, growing middle-class population and inflating income levels of consumers in these countries. Looking forward, the market is projected to reach a value of \$398 billion by 2024, at a CAGR of nearly 7% during 2019-2024.

Company Overview

Incorporated in the year 1996, our Company is into developing, manufacturing and marketing a broad range of healthcare products including nutraceutical, cosmeceutical and Ayurveda products. With an operating history of more than two decades, we are primarily known for our premium range of nutraceutical, Ayurveda and cosmeceutical products. In the present competitive era of medicines and food supplements, we aim to distinguish our identity by focusing on ways to bridge the nutrition gap which is a recognised cause of many diseases. Our Company has identified over 50 consumer wellness goals and over 200 diseases, disorders, disabilities which can be prevented by meeting RDA of micronutrients and we have innovated and developed cost effective products that are unique and differentiated to meet consumers' wellness goals.

In 2010, we set up our own manufacturing facility at SIDCUL Pantnagar, Rudrapur, Uttarakhand. The quality of our products is evidenced by the number of quality certifications that our Company has obtained from various local and international accreditation agencies. Our facility complies with GMP and WHO GMP for its health / diet supplements and ayurvedic products. We have also obtained FSSAI license for our products. Our Company is also an ISO 9001:2015 certified for Management System for manufacturing and supply of Nutraceutical & Pharmaceutical Products. Spread over 3,536 Sq. mts., our manufacturing facility is equipped with the requisite plant and machineries including Effluent Treatment Plant and other resources required for our manufacturing process. Our R&D capabilities enable us to support our growth strategy by developing new products and process which enhance our range of products and services. We have a diversified product portfolio with our product basket consisting of more than 1,500 products used for various purposes such as hair care, skin care, heart care, immunity building, etc. We have the ability to supply tailored wellness products in various forms such as tablets, capsules, gel, liquids, ointments, powder, pastes and other delivery formats.

We mainly develop and market differentiated healthcare products specializing in nutraceutical and cosmeceutical products, which we commercialize through different revenue channels that takes the products solutions to the consumers which includes network of distributors, influencers, direct to consumers and e-commerce channel for our domestic sales. We have a training centre for our influencers wherein we train them about our product offerings and offer them commission to market our products. As on date of this Annual Report, we have around 6,100 influencers. We have also set up our own portal for commercialization of our products and their distribution through e-commerce. The online portal for e-commerce is www.beyoungstore.com. Our Company has been receiving encouraging response in this direction from consumers. We have a PAN India presence in domestic markets. To expand our reach, we have also entered into 2 distributorship agreements with foreign distributors situated in Kenya and Tanzania respectively.

Our Promoters, Dr. Minto P. Gupta and Mr. Hitesh Patel have played an instrumental role in the growth of our Company. Our promoter Dr. Minto P. Gupta has been associated with our Company since incorporation and our Company may be rightly called the brainchild of Dr. Minto P. Gupta. He is the guiding force behind the research and development capabilities of our Company and under his guidance we have been able to successfully execute our business strategies over the years. Our other promoter Mr. Hitesh Patel joined hands with our Company in 2008 and has since then headed the Company for organic and strategic growth by tapping the expansion opportunities available at different phases of our business cycle. With our experienced and dedicated management, we have recorded an annual turnover of Rs. 4224.41 lakhs in 2020 from Rs. 704.68 lakhs in the year 2014. The said growth was achieved despite our manufacturing unit facing a natural calamity in 2013 which took a span of time for revival.

We believe that one of our USP is we are dealing in FMCH products, which is a fast growing sector. The emerging consumer habits and exposure through digital media and internet is disrupting the wellness sector. The consumers are deeply concerned with management of diseases, which has raised the need of awareness for wellness and prevention and alternative healthcare solutions at an inflection point and we aim to serve the emerging health care consumer with innovative preventive healthcare wellness solutions.

The salient features of our business model are as follows:

- A robust well researched best in the Industry, distinguished Product Portfolio to Meet 52 wellness goals of consumers
- Tested, approved, certified products FSSAI approved
- 73 unique proprietary formulas and 212 distinguished formulas
- Established farm to factory efficient; process-controlled, best price sources of high quality potent raw materials
- Adequate, efficient cost effective, SOP driven, WHO-GMP Manufacturing, capabilities and Capacities
- Running an online store www.beyoungstore.com with over 200,000 consumers selling 70+ products clocking in 1.75-2 Crores revenue per month run rate.
- Functional consumer servicing system serving 100 plus orders a day
- Effective consumer education model both online and offline
- Efficient PIP (Product Information Personnel) recruitment and gratifying system
- A large base of PIP (6000+) in operating geographies
- Effective in-house PIP training and development system
- High operating efficiency with material cost at 30% and expenses at 30% efficiently managing teeth to tail ratio, limiting fixed expenses and cost
- Highly qualified 3-member senior key management team mix of experience and youth
- An expanding #beyoungbharat mission that promotes, achieving RDA (Required Daily Amount) of nutrients and leading a more productive, efficient, energy filled, satisfying and most important a DISEASE-FREE HIGH-QUALITY LIFE, lifelong is slowly and gradually becoming popular and gaining acceptance.

Key leadership values that drive the Company

We achieve our vision by helping people discover their potential and reach their wellness goals by offering products and opportunities for the future as well as by sharing generously with the global community. To help us realize that vision, we have five enduring values that the business is primarily built on:

Association: DHC is built on the concept of relationship between our stakeholders. The association that exists among the founding families, employees, and influencers, shareholders is our most prized

possession. We always try to do what is in the long-term best interest of our stakeholders, in a manner that increases trust and confidence.

Integrity: Integrity is essential to the success of our business. We do what is right. DHC's success is measured not only in economic terms, but by the respect, trust and credibility earned.

Personal Worth: We also acknowledge the uniqueness in each and every individual. Every person is worthy of respect and deserves fair treatment and the opportunity to succeed to the fullest extent of his or her potential.

Achievement: We are builders and encouragers. We strive for excellence in all we do. Our focus is on continuous improvement, progress and achievement of individual as well as group wellness goals. We anticipate change, respond swiftly to it, take action to get the job done, and gain from our experiences. We encourage creativity and innovation.

Personal Responsibility: Each individual is responsible and accountable for achieving personal goals and also for making 100 percent efforts to help achieve the corporate or team goals. By helping people help themselves, we further the potential for individual and shared success. We also have the responsibility to be good citizens in the communities where we live and work

Strength

- Large number of registered / buyers Health Conscious Consumers
- Large number of PIP (Product Information Personnel)
- Large number of SI (Sales Influencers)
- Online Resellers HS (Home Shoppe) -Entrepreneur Start Up program
- Online E commerce portal
- Customer supply chain
- Online communications channel
- Nutraceutical product line
- AYUSH Personal care product line
- In built infrastructure to scale-up
- Full control on supply chain
- Profitable P&L numbers

Weaknesses/ Limitations

- Presence in Predominant Hindi speaking / understanding states
- Publicity Only by word of mouth; local events.
- Not updated with latest technological options available
- Product range limited to Nutraceutical and some Personal care
- Products of Deccan Health Care only
- Web support outsource
- In adequate data analytics

Opportunities/tailwinds

- Increasing self-care for mild to moderate diseases disorders
- Higher inclination of consumers to buy online
- COVID19 increasing Health & fitness concerns
- High Disposable incomes
- Increasing practice towards Prevention
- Higher demand from body system

- Increase in number of years we live (life expectancy)
- Availability of Better proven science-based products
- Escalating Healthcare cost and low availability
- Favorable government attitude to alternative healthcare
- Existing Limited competition from online Consumer Healthcare Stores Serving OTC consumer products
- Low competition in comparison to BYS size and BYS P&L Numbers
- Availability of better technologies to fast track online processes

Threat

- Medical fraternity attempts to reject the concept of self-Care
- Change in Government regulations
- More stringent product quality assurance compliances
- More stringent regulations on E commerce

Segment Wise or Product Wise Performance

Your Company is not required to bifurcate segment wise or product wise categories.

Outlook

The Indian nutraceutical industry has shown great potential and is well-poised for growth. On the domestic front, there is significant under penetration of nutraceuticals. New initiatives such as Ayushman Bharat, rising penetration of health insurance, improvement in medical infrastructure, growth of diagnostic networks and increased awareness will lead to growth in the sector in the long term.

Focus on Preventive Healthcare: at present, all the major Indian pharmaceutical giants are ventured into Nutraceuticals with the belief that the future is for preventive therapy instead of curative therapy. Awareness and emphasis on preventive therapy has helped to strengthen the consumption of nutraceuticals in the country. Consumers especially from tier 1 cities are becoming progressively health conscious viz-a-viz realizing the importance of dietary supplements in dealing with the ill-effects of the rapidly changing pace of life.

Rapid Retail Growth and E-Commerce: Indian retail sector accounts for 10% of the Gross Domestic Product (GDP) and contributes to 8% of the total employment. India's retail market is expected to double to US\$ 1.3 Trillion by 2020 from US\$ 600 Billion in 2015 driven by income growth, urbanization and attitudinal shifts. The retail spending in major cities of India stood at US\$ 57.5 Billion. Apart from this, India is likely to become the world's largest budding e-commerce industry with the significant investments and substantial number of internet users. Indian e-commerce market will showcase a market size of around US\$ 100 Billion by 2020 from US\$ 22 Billion marked in 2015. Rise in e-commerce growth will bolster the availability of Nutraceuticals online by different manufacturers due to ease and comfort.

Strategy

Long-term Strategy Develop an agile organization by concentrating on key business enablers:

- Compliance: Compliance with varied international regulations to maintain high quality standards and global customer base
- Customer service: Sharp awareness of customer needs and determined towards delivering quality products in a timely manner

- Capacity and capabilities enhancement: Sufficient capacity to meet demand as well as respond to market opportunities and capabilities enhancement to keep up with technology advancements
- Cost leadership: Continuous improvement of the Company's manufacturing process along with mechanisation to be more competitive and to stay longer in the market place
- Continuity: Business continuity through risk mitigation and sustainability measures

Risk and Concerns

Our business is subjected to various risks and uncertainties and our results of operations and financial conditions are affected by numerous factors including the following:

- Supply and availability of raw material/traded goods;
- Competition from existing and new entrants;
- Performance of our distribution channel;
- Brand image;
- Rate of interest policies;
- Economic and Demographic conditions; and
- Changes in laws and regulations that apply to Nutraceutical Industry in domestic and overseas market.

Internal Control Systems & Their Adequacy

DHCL has adequate internal control systems and procedures, covering all financial and operating functions commensurate to its size and nature of operations. A strong internal control framework is among the important pillars of corporate governance and the Company strives to enhance it consistently. It is designed to provide reasonable assurance regarding maintenance of accounting controls and assets from unauthorised use or losses.

Company has appointed M/s SLR & Associates, Chartered Accountants, Hyderabad (FRN:0158745) to oversee and carry out internal audit of its activities for the FY 2020-21. The audit is based on an internal audit plan, which is reviewed in consultation with the statutory auditors and approved by the audit committee.

Discussion on Financial Performance with respect to the Operational Performance

The Company continued to show good financial performance in the fiscal year 2019-20, our total revenue recorded is Rs. 4224.41 lakhs for the financial year 2019-20 as compared to Rs. 4424.48 lakhs for the financial year 2018-19 the change is impacted by slowdown in the economy due to Covid-19 pandemic.

Significant changes (i.e. change of 25% or more as compared to the immediately previous financial years) in Key Financial Ratios, along with explanation are as under:

S. No.	Particulars	FY 2019-20	FY 2018-19	Change
1	Debtor Turnover Ratio	2.12	2.39	(11.49)
2	Inventory turnover	0.48	0.59	(18.89)
3	Interest Coverage ratio	56.31	15.07	273.68
4	Current ratio	4.84	4.73	2.39

5	Debt- Equity Ratio	0.22	0.25	(12.07)
6	Operating Profit margin	33.66	35.19	(4.35)
7	Net Profit Margin	23.88	32.73	(27.04)
8	Return on net Worth	13.23	21.89	(39.55)

Material Developments in Human Resources / Industrial Relations, Including Number of People Employed

Your Company's employee strength as on 31st March, 2020 was 96. The company has taken steps to improve processes for better talent acquisition, performance evaluation, merit recognition, and higher productivity. The Company has also undertaken initiatives to build stronger employee engagement and talent retention. Core policies to enhance efficiencies have been implemented.

**By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED**

Place: Hyderabad
Date: 05.09.2020

DR. MINTO P. GUPTA
Managing Director

HITESH PATEL
Director

INDEPENDENT AUDITOR'S REPORT

To
The Members of
DECCAN HEALTH CARE LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the Standalone Financial Statements of **DECCAN HEALTH CARE LIMITED** (“the Company”), which comprise the balance sheet as at 31st March 2020, and the statement of Profit and Loss, and Statement of Cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, and profit/loss, and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon and we do not provide a separate opinion on these matters and there are no matter during the year to be reported as key Audit Matters.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexure to Board's Report (but does not include the standalone financial statements and our auditor's report thereon) and the rest of the Annual Report (the "Other Information"). The Other information is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

When we read the other information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance, of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the '**Annexure A**' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid Standalone Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st march, 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31st march, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197 of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
 - (g) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
 - (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company has disclosed the impact of pending litigation which should require to disclose on its financial position.
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W

Keyur Shah
Proprietor
M. No. 153774
UDIN: 20153774AAAABY3509

Date: 31-07-2020
Place: Ahmedabad

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & ‘Regulatory Requirement’ of our report of even date to the Standalone Financial Statements of the Company for the period ended March 31, 2020:

Fixed Assets:

- a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
- b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the Period and no material discrepancies between the books records and the physical fixed assets have been noticed.
- c) The Title deed of immovable properties are held in the name of the company.

Inventory:

- a) The management has conducted the physical verification of inventory at reasonable intervals.
- b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.

Loans given by the Company:

The company has not granted loans & advances to parties covered under section 189 of the Act

Loans to directors & Investment by the Company:

In our opinion and according to the information and explanations given to us, the company has complied with the provision of section 185 & 186 of the Companies Act, 2013 in respect of loans etc.

Deposits

The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

Cost Records

As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.

Statutory Dues:

- a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-

Tax, Sales Tax, Goods and Services Tax, Service Tax, Duty of Customs, Duty of Excise, Value Added tax, Cess and any other statutory dues with the appropriate authorities except as mentioned below:

Name of the Statute	Nature of Dues	Amount (Rs. In Lakhs)	Period to which the amount relates	Due Date of payment	Date of payment
EPF & MP Act,1952	Employer Contribution	0.35	April,2019	15 th of May	
		0.15	May,2019	15 th of June	
		0.12	June,2019	15 th of July	
		0.12	July,2019	15 th of Aug	
		0.12	Aug,2019	15 th of Sep	
	Employee Contribution	0.60	April,2019	15 th of May	
		0.14	May,2019	15 th of June	
		0.11	June,2019	15 th of July	
		0.11	July,2019	15 th of Aug	
		0.11	Aug,2019	15 th of Sep	
ESIC Act,1948	Employer Contribution	0.15	April,2019	15 th of May	
		0.05	May,2019	15 th of June	
		0.04	June,2019	15 th of July	
		0.02	July,2019	15 th of Aug	
		0.02	Aug,2019	15 th of Sep	
	Employee Contribution	0.26	April,2019	15 th of May	
		0.13	May,2019	15 th of June	
		0.12	June,2019	15 th of July	
		0.08	July,2019	15 th of Aug	
		0.08	Aug,2019	15 th of Sep	
Income Tax Act, 1961	Tax Deducted at Source	1.69	Aug,2019	15 th of Sep	

- b) According to the information and explanation given to us, there are no dues of income tax, sales tax, Goods & Service Tax, service tax, duty of customs, duty of excise, value added tax outstanding on account of any dispute except as mentioned below:

(Rs. in Lakhs)

Nature of Statute	Nature of Dues	Forum Where Dispute is pending	Period to Which the Amount Relates (Assessment Year)	Amount
Income Tax Act, 1961	Income Tax	CPC	2001-02	1.15 /-
Income Tax Act, 1961	Income Tax	CPC	2009-10	1.10 /-
Income Tax Act, 1961	Income Tax	Jurisdictional Assessing Officer	2010-11	5.26 /-
Income Tax Act, 1961	Income Tax	Assessing Officer	2017-18	451.12 /-
Income Tax Act, 1961	Income Tax	CPC	2019-20	505.91 /-

Repayment of Loans:

In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan from the government and has not issued any debentures. The Loans taken from financial institutions have been properly disclosed in Financial Statements & are repaid at regular intervals.

Utilization of IPO & FPO:

Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised monies by way of initial public offer or further public offer including debt instruments.

Reporting of Fraud:

Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the period.

Approval of Managerial Remuneration:

Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;

NIDHI Company:

In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii) of the Order are not applicable to the Company.

Related Party Transaction:

In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.

Private Placement or Preferential Issues:

Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.

Non Cash Transaction:

The company has not entered into non cash transaction with the directors or their relatives and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

Register under RBI Act, 1934:

In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

**For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W**

**Keyur Shah
Proprietor
M. No. 153774
UDIN: 20153774AAAABY3509**

**Date: 31-07-2020
Place: Ahmedabad**

“Annexure B” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of **DECCAN HEALTH CARE LIMITED**

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **DECCAN HEALTH CARE LIMITED** (“the Company”) as of March 31, 2020 in conjunction with our audit of the Standalone Financial Statements of the Company for the period ended on that date.

Management’s Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting with Reference to these Standalone Financial Statements

A company's internal financial control over financial reporting with reference to these Standalone Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting with reference to these Standalone Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements

Inherent Limitations of Internal Financial Controls over Financial Reporting With Reference to these Standalone Financial Statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to these Standalone Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Standalone Financial Statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these Standalone Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020 based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W**

**Keyur Shah
Proprietor
M. No. 153774
UDIN: 20153774AAAABY3509**

**Date: 31-07-2020
Place: Ahmedabad**



DECCAN HEALTH CARE LIMITED

CIN-U72200TG1996PLC024351

Statement of Assets and Liabilities as at 31st March, 2020

(Rs. in lakhs)

	Particulars	Note No.	As at 31st March, 2020 Audited	As at 31st March, 2019 Audited
I.	EQUITY AND LIABILITIES			
(1)	Shareholder's Funds			
	(a) Share Capital	2	1,571.34	1,571.34
	(b) Reserves and Surplus	3	6,051.86	5,043.12
(2)	Share Application Money pending allotment			
(3)	Non-Current Liabilities			
	(a) Long-Term Borrowings	4	86.85	87.09
	(b) Deferred Tax Liability	5	213.68	209.23
	(c) Long Term Provisions	6	15.38	16.74
(4)	Current Liabilities			
	(a) Trade Payables	7	705.97	770.99
	(b) Other Current Liabilities	8	463.44	423.57
	(c) Short-Term Provisions	9	190.47	163.25
	TOTAL		9,298.99	8,285.33
II.	ASSETS			
(1)	Non-Current Assets			
	(a) Fixed Assets			
	(i) Tangible Assets	10	2,124.83	2,085.46
	(ii) Intangible Assets		-	-
	(iii) Capital work-in-progress		-	-
	(b) Long-Term Loans and Advances	11	184.78	187.39
	(c) Other Non-Current Assets	12	403.40	303.66
(2)	Current Assets			
	(a) Inventories	13	3,790.06	3,209.41
	(b) Trade Receivables	14	2,056.10	1,937.78
	(c) Cash and Cash Equivalents	15	344.53	447.83
	(d) Short-Term Loans and Advances	16	395.29	113.80
	TOTAL		9,298.99	8,285.33

The accompanying notes 1 to 33 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

For & on behalf of Board of Directors

Keyur Shah
Proprietor
M.No. 153774

Minto P Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 31st July,2020

Uttam Kumar Singh
Chief Financial Officer
PAN-AFWPS4957D

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



DECCAN HEALTH CARE LIMITED

CIN-U72200TG1996PLC024351

Statement of Profit & Loss for the Year ended on 31st March, 2020

(Rs. in lakhs)

	Particulars	Note No	For the Year Ended 31st March, 2020 Audited	For the Year Ended 31st March, 2019 Audited
I.	Revenue from Operations	17	4,224.41	4,424.79
II.	Other Incomes	18	5.72	8.40
III.	Total Revenue (I + II)		4,230.13	4,433.19
IV.	Expenses:			
	Cost of Materials Consumed	19	2,338.65	1,935.48
	Changes in Inventories of Finished Goods and Work-in-Progress	20	(663.78)	(421.48)
	Employee Benefit Expenses	21	433.38	409.22
	Other Expenses	22	948.65	821.08
	Finance Costs	23	18.32	103.57
	Depreciation and Amortization Expense	10	141.73	128.64
	Total Expenses		3,216.95	2,976.51
V.	Profit/ Loss before Exceptional Items and Tax (III - IV)		1,013.18	1,456.68
VI	Exceptional Items		-	-
VII	Profit before Tax (V-VI)		1,013.18	1,456.68
VIII	Tax Expense:			
	(1) Provision for Income Tax		-	-
	Income Tax (MAT)	177.02		
	Less: MAT Credit Entitlement	(177.02)		
	(2) Deferred Tax		4.44	8.63
IX	Profit/ (Loss) for the period (VII-VIII)		1,008.74	1,448.05
X	Earnings Per Equity Share			
	(1) Basic		6.42	10.29
	(2) Diluted		6.42	10.29

The accompanying notes 1 to 33 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

Keyur Shah
Proprietor
M.No. 153774

Place: Ahmedabad
Date : 31st July,2020

For & on behalf of Board of Directors

Minto P Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Uttam Kumar Singh
Chief Financial Officer
PAN-AFWPS4957D

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



DECCAN HEALTH CARE LIMITED

CIN-U72200TG1996PLC024351

Cash Flow Statement for the Year Ended 31st March, 2020

(Rs. in lakhs)

	PARTICULARS	For the Year Ended 31st March, 2020	For the Year Ended 31st March, 2019
A	Cash Flows from Operating Activities		
	Net Profit before tax and Extraordinary items	1,013.18	1,456.68
	Adjustments for :		
	Depreciation	141.73	128.64
	Interest Expense	18.32	103.57
	Interest Income	(1.36)	(0.50)
	Operating Profit before Working Capital Changes	1,171.87	1,688.39
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	(118.32)	(170.37)
	(Increase)/Decrease in Inventory	(580.65)	(1,248.26)
	Increase/(Decrease) in Provisions	25.87	(40.04)
	(Increase)/Decrease in Non Current Asset	(99.74)	(43.24)
	(Increase)/Decrease in Short Term Loans and Advances	(281.50)	1.70
	Increase/(Decrease) in Trade Payables	(65.01)	202.36
	Increase/(Decrease) in Current Liabilities	50.94	(128.40)
	Cash Generated from Operations	103.46	262.14
	Tax Paid	-	-
	Net Cash from Operating Activities	103.46	262.14
B	Cash Flows from Investing Activities		
	(Increase)/Decrease in CWIP	-	351.29
	Purchase of Fixed Assets	(181.10)	(443.49)
	Interest Income	1.36	0.50
	Other Statutory Adjustment	-	(1,663.56)
	(Increase)/Decrease in Long Term Loans and Advances	2.61	602.70
	Net Cash from Investing Activities	(177.13)	(1,152.56)
C	Cash Flows from Financing Activities		
	Share Capital	-	221.20
	Securities Premium	-	1,990.80
	Interest Expense	(18.32)	(103.57)
	Increase/(Decrease) in Long Term Borrowing	(11.31)	(801.63)
	Net Cash from Investing Activities	(29.63)	1,306.80
D	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(103.29)	416.38
E	Cash and Cash Equivalents at the beginning	447.82	31.44
F	Cash and Cash Equivalents at the end (D+E)	344.53	447.83

The accompanying notes 1 to 33 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

Keyur Shah
Proprietor
M.No. 153774

Place: Ahmedabad
Date : 31st July,2020

For & on behalf of Board of Directors

Minto P Gupta Hitesh Patel
Managing Director Director
DIN-00843784 DIN-02080625

Uttam Kumar Singh Sheena Jain
Chief Financial Officer Company Secretary
PAN-AFWPS4957D PAN-BCJPJ9626H

Note No: 1

A. Significant Accounting Policies:

The Accounting policies set out below have been adopted in preparation and presentation of financial statement and applied consistently to the period presented in this financial statement.

B. Disclosure of Accounting Policies:

a. Basis of Preparation:

These financial statement have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

b. Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles require the management to make estimates and assumptions that affect the reported amounts of Assets and Liabilities and disclosure of Contingent Liabilities at the date of the financial statements and the result of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Significant estimates used by the management in the preparation of these financial statements include provisions for bad and doubtful debts. Any revision to accounting estimates is recognized prospectively.

c. Accounting Convention and Revenue Recognition:

The Financial Statements have been prepared on a going concern basis in accordance with historical cost convention except for such fixed assets which are revalued. Both Income and Expenditure are recognized on accrual basis.

Revenue from Sales is recognized when practically all risks and rewards of ownership are transferred to the buyer and there is no effective control of the seller as the owner, this usually occurs upon dispatch of the goods. Gross sales shown in the Statement of Profit & Loss are inclusive of Excise duty but exclude discounts, CST, VAT & Goods & Service Tax. Net Sales are shown after deducting Excise duty which is disclosed at appropriate places. Interest income is recognized on receipt basis, and not on a time proportion basis, taking into accounts the amount outstanding and rate applicable.

Revenue are accounted Net of Goods & Service Tax (GST), Excise Duty, Taxes and Sales Returns. Other Items of Revenue are recognized in accordance with AS-9.

d. Cash Flow Statement: AS-3

The Company has prepared Cash Flow Statement as per the AS-3.

Cash flows are reported using the Indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

e. Retirements Benefits:

Staff benefits arising out of retirements / death, comprising of contributions to Provident Fund, Superannuation & Gratuity Schemes, accrued Leave Encashment and other post-separation benefits are accounted for on the basis of an independent actuarial valuation, in accordance with AS-15. The actuarial liability is determined with reference to employees at the end of each financial year.

Expenses for defined benefit gratuity payment plans are calculated as at the balance sheet date by independent actuaries in the manner that distributes expenses over the employees working life. These commitments are valued at the present value of the expected future payments, with consideration for calculated future salary increases, using a discounted rate corresponding to the interest rate estimated by the actuary having regard to the interest rate on Government Bonds with a remaining term i.e. almost equivalent to the average balance working period of employees.

The Company has adopted accounting standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed under the notes to financial Statement.

f. Property, Plant & Equipment:

Property, Plant and Equipment are stated at cost net off recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any. Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use, net charges on foreign exchange contracts and arrangements arising from exchange rate variations attributable to the assets. Expenditure on additions, improvements and renewals is capitalized and expenditure for maintenance and repairs is charged to profit and loss account.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow the entity and the cost can be measured reliably.

Depreciation on property, plant and equipment is provided using Straight Line Method over the useful life of the Asset. Depreciation in respect of addition to assets has been charged on pro rata basis with reference to the period of use of such asset.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de recognition of a property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized

g. Accounting for Investments:

Long term investments are stated at cost. However, provision for diminution is made to recognize any decline, other than temporary, in the value of long term investments. Current Investments are stated at the lower of cost and fair value.

h. Accounting for Intangible Assets:

Intangible assets are capitalized at cost if:

- a. It is probable that the future economic benefits that are attributable to the asset will flow to the company;
- b. The company will have control over the assets;
- c. The cost of these assets can be measured reliably and is more than 10,000/- & this is in accordance with AS-26.

i. Accounting for Borrowing Costs:

Borrowing cost relating to acquisition/ construction of qualifying assets are capitalized until the time all substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use/sale. Borrowing costs that are attributable to the projects are charged to the respective projects. All other borrowing costs, not eligible for capitalization, are charged to revenue accounts.

j. Accounting & Valuation for Inventories:

- i) Materials, Stores & Spares, Tools and Consumables are valued at Cost or Market Value, whichever is lower, on the basis of First In First Out method reflecting the fairest possible approximation to the cost incurred in bringing the items of Inventory to their present location and condition.
- ii) Finished Stock of completed products is valued at lower of Cost or Net Realizable Value on the basis of actual identified units. Cost being determined by including cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realizable value determined by excluding all payable statutory dues and direct sales expenses.
- iii) Scrap is valued at Net Realizable Value.
- iv) Work in process in respect of activities is valued at estimated cost.

k. Accounting for Taxes on Income:

- i) Provision for tax for the year comprises current Income Tax and Deferred Tax and is provided as per the Income Tax Act, 1961.
- ii) Deferred tax resulting from timing differences between the book and the tax profits is accounted for, at the current rate of tax, to the extent that the timing differences are expected to crystallize. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in the future; however where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets/ liabilities are reviewed as at each balance sheet date.

l. Provisions, Contingent Liabilities and Contingent Assets:

Provisions are recognized for liabilities that can be measured only by using a substantial degree of estimation, if

- i) The Company has a present obligation as a result of a past event;
 - ii) A probable outflow of resources is expected to settle the obligation; and
 - iii) The amount of the obligation can be reliably estimated.
- iv) Reimbursement expected in respect of expenditure required to settle a provision is recognized only when it is virtually certain that the reimbursement will be received.

Contingent Liability is disclosed in the case of:

- i) A present obligation arising from a past event, when it is not probable that an outflow of resources will be required to settle the obligation;
- ii) A possible obligation, unless the probability of outflow of resources is remote. Contingent Assets are neither recognized nor disclosed.

m. Earnings per Share:

The earnings considered in ascertaining the companies earning per share comprise net profit after tax and includes the post-tax effect of any extra-ordinary/exceptional item is considered. The number of shares used in computing basic earnings per share is the weighted average number of shares outstanding during the year.

The no. of shares used in computing diluted earnings per share comprises the weighted average no. of shares considered for deriving basic earnings per share and also the weighted average no. of equity shares that could have been issued on the conversion of all dilutive potential equity shares.

n. Accounting for Impairment of Assets:

Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired.

Impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of carrying amount over the higher of the asset's net sale price or present value as determined above.

o. Related Party Disclosures:

The Company as required by AS-18 furnishes the details of Related Party Disclosures in the notes to financial statements.

p. Foreign Currency Transaction:

- i) The transactions in foreign currencies are converted into Indian Rupees at the rates of exchange prevailing on the date of transactions.
- ii) The balances in Current Assets and Current Liabilities in foreign currencies at the date of Balance Sheet have been converted into Indian Rupees at the rate of exchange prevalent on that date as per RBI reference rate. The resultant net gain /loss arising out of such foreign exchange translations is taken to Profit and Loss Account except in respect of such differences related to acquisition of Property, Plant and Equipment from a country outside India which are capitalized as a part of cost of respective Property, Plant and Equipment.
- iii) In respect of transactions covered by Foreign Exchange Forward Contracts, the difference between the forward rate and exchange rate at the inception of contract is recognized as income or expenses over the life of the contract

DECCAN HEALTH CARE LIMITED
Notes to the Financial Statements as at 31st March, 2020

2 Share Capital

(Rs. In Lakhs)

Particulars	As at 03/31/2020 Rs.	As at 31-03-2019 Rs.
Authorised Capital		
18000000 Equity Shares of Rs.10/- each (PY.18000000 Equity Share of Rs.10 /- each)	1,800.00	1,800.00
	1,800.00	1,800.00
Issued, Subscribed and Paid up		
1,57,13,430 Equity Shares of Rs.10/- each (PY.1,57,13,430 Equity Shares of Rs. 10/- each)	1,571.34	1,571.34
	-	
Total	1,571.34	1,571.34

A) The company has only one class of equity share having at par value of Rs.10/- per share.

B) During the year 31st March, 2020 ,the amount of share dividend recognised to euity share holder was "nil" (P.Y. "nil")

C) Reconciliation of number of shares outstanding and amount of share capital

Particulars	As at March 31, 2020		As at March 31, 2019	
	No. of Shares	Amounts	No. of Shares	Amounts
Shares outstanding at the beginning of the year	15,713,430	157,134,300	13,501,430	135,014,300
Shares issued duing the year	-	-	2,212,000	22,120,000
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	15,713,430	157,134,300	15,713,430	157,134,300

D) Detail of shareholder holding more than 5% share in the company is given below :-

Particulars	As at March 31, 2020		As at March 31, 2019	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Minto Pursottam Gupta	2,107,667	13.41	2,107,667	13.41
Meenakshi Gupta	1,707,333	10.87	1,707,333	10.87
Hitesh M Patel	3,009,214	19.15	3,925,214	24.98
Kent RO System Limited	968,800	6.17	968,800	6.17
Total	7,793,014.00	49.59	8,709,014.00	55.42

3 Reserves and Surplus

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Security Premium		
Opening Balance	5,373.59	3,967.86
Add: Dunring the year	-	1,990.80
Less : Issue Exps / Transaction Cost regarding Inital Public Offer	-	(585.07)
Closing Balance (A)	5,373.59	5,373.59
Profit & Loss Account		
Opening balance	(330.47)	(700.03)
Add: Profit For the year	1,008.74	1,448.05
Less : Other Adjustment	-	(1,078.49)
Closing Balance (B)	678.27	(330.47)
Total(A+B)	6,051.86	5,043.12

4 Long Term Borrowings

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
(a) Term Loan (Secured)		
From Bank		
Axis Bank (Refer Note No. 33)	33.46	46.43
HDFC Bank - I (Refer Note No. 33)	25.80	35.95
HDFC Bank - II (Refer Note No. 33)	21.00	-
HDFC Bank - III (Refer Note No. 33)	16.43	-
Kotak Mahindra Bank (Refer Note No. 33)	10.00	35.62
Less:- Current Maturity	(42.59)	(53.66)
	64.10	64.34
(b) Loan and Advances from Directors and Related Parties		
(i) From Directors	10.00	10.00
	10.00	10.00
(c) Loan from Member / Share Holders		
Value Worth Capital Management Pvt Ltd	12.75	12.75
	12.75	12.75
Total	86.85	87.09

5 Deffered Tax Liability

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Opening Balance of Deffered tax Laibility	209.23	200.60
Add: Provision for the year	4.44	8.63
Closing Balance of Deffered tax Laibility	213.68	209.23
Total	213.68	209.23

6 Long-Term Provisions

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Provision for Employee Benefits (Non Current)	15.38	16.74
Total	15.38	16.74

7 Trade Payables

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
- Due to Micro , Medium & Small Enterprises	-	-
- Others	705.97	770.99
Total	705.97	770.99

Note: The management is in process of identifying parites which are covered under MSME, The amount relating to MSME are disclosed to the extent identified.

8 Other Current Liabilities

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Current Maturities of Long-Term Debt	42.59	53.66
Advance from Customers	18.48	93.04
Duties & Taxes	77.14	81.16
Other Current Liabilities	325.23	195.71
Total	463.44	423.57

9 Short Term Provisions

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Provision for Employee Benefits	0.44	1.14
Provision for Income Tax	182.28	162.11
Provision for Others	7.75	-
Total	190.47	163.25

11 Long-Term Loans and Advances

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Security Deposits (Unsecured considered good)	28.19	29.61
Loans and advances to Related Parties	156.60	157.78
Total	184.78	187.39

12 Other Non Current Assets

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
R&D Product Development Expenses	224.61	138.91
TDS/ MAT recoverable	178.79	164.75
Total	403.40	303.66

13 Inventories

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Raw Materials and Components	2,096.20	2,179.33
Work-in-Progress	1,184.12	373.10
Finished Goods	509.74	656.98
Total	3,790.06	3,209.41

14 Trade Receivables

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Unsecured, Considered Good		
- Outstanding for a period less than six months from the date they are due for payment	341.36	866.27
- Outstanding for a period exceeding six months from the date they are due for payment	1,154.04	340.14
Secured Considered Good	560.70	635.81
Unsecured Considered Doubtful		95.56
Total	2,056.10	1,937.78

15 Cash and Cash Equivalents

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Balances with banks		
- On Current Accounts	7.80	213.58
- Deposits with original maturity (having original maturity more than a year)	2.28	1.93
Cash on hand/Imprest	334.45	232.32
Total	344.53	447.83

16 Short-Term Loans and Advances

(Rs. In Lakhs)

Particulars	As at 31-03-2020 Rs.	As at 31-03-2019 Rs.
Unsecured Considered good		
Other Advances	-	44.40
	-	44.40
Security Deposits		
Un-Secured Considered Good	-	42.12
	-	42.12
Advance To Creditors	391.52	19.06
Prepaid Exps	3.60	6.01
Other Current Assets	0.17	2.21
	395.29	27.28
Total	395.29	113.80

DECCAN HEALTH CARE LIMITED										
Depreciation Schedule for the Year ended 31-03-2020										
(Rs. In Lakhs)										
10	Fixed Assets	GROSS BLOCK				DEPRECIATION			NET BLOCK	
		PARTICULARS	AS AT 01.04.2019	ADDITIONS DURING THE YEAR	TOTAL AS AT 31.03.2020	UPTO 01.04.2019	FOR THE YEAR	UPTO 31.03.2020	NET CARRYING AMOUNT AS AT 31.03.2020	NET CARRYING AMOUNT AS AT 31.03.2019.
1	Land (Lease Hold)	28.41	-	28.41	-	-	-	28.41	28.41	
2	Factory Building	1,280.55	152.42	1,432.97	262.46	44.45	306.91	1,126.06	1,018.09	
3	Plant & Machinery	1,154.34	-	1,154.34	504.09	54.83	558.92	595.42	650.25	
4	R&D (Machinery)	85.96	-	85.96	29.00	4.08	33.08	52.88	56.96	
5	Furniture & Fixture	98.91	3.67	102.58	59.44	6.39	65.83	36.75	39.47	
6	Electrical Appliances	47.36	0.26	47.62	2.73	2.25	4.99	42.63	44.63	
7	Computer & Software	94.87	5.99	100.85	93.07	2.44	95.50	5.35	1.80	
8	Office Equipments	38.86	4.06	42.92	16.55	2.61	19.16	23.76	22.31	
9	Air Conditions	14.74	0.67	15.41	8.10	0.97	9.07	6.35	6.65	
10	Vehicles	326.13	14.03	340.16	109.24	23.70	132.94	207.22	216.90	
	Sub Total	3,170.13	181.10	3,351.23	1,084.67	141.73	1,226.40	2,124.83	2,085.46	
	Previous Year	2,726.64	443.49	3,170.13	956.03	128.64	1,084.67	2,085.46	1,770.61	

DECCAN HEALTH CARE LIMITED
Notes to the Financial Statements for the Year ended 31st March, 2020

17 Revenue From Operation (Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Sale of Products - Domestic	4,224.41	4,403.67
- Export	-	21.12
Total	4,224.41	4,424.79

18 Other Incomes (Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Interest Income	1.36	0.50
Discount Received	1.54	1.47
Other Non-Operating Income	2.82	6.43
Total	5.72	8.40

19 Cost of Material Consumed (Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Opening Stock	2,179.33	1,352.55
Purchases	2,255.52	2,762.25
Less Closing Stock	2,096.20	2,179.33
Total	2,338.65	1,935.48

20 Changes in Inventories of Finished Goods and Work-in-Progress (Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Opening Stock (Finished Goods & WIP)	1,030.08	608.60
Closing Stock (Finished Goods & WIP)	1,693.86	1,030.08
Total	(663.78)	(421.48)

21 Employee Benefit Expenses (Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Salaries and Wages	413.90	405.37
Contribution to Provident Fund and Other funds & Staff Welfare Exps	19.47	3.86
Total	433.38	409.22

22 Other Expenses

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Administration Charges	20.86	16.77
Auditors' Remuneration	2.50	2.50
Casual Labour Charges & Wages	41.54	73.48
Communication,Courier & Telephone Expenses	11.07	56.94
Consumable & Manufacturting Expenses	5.59	2.72
Directors Sitting Fees	0.25	-
Freight , Cartage & Packing	29.49	10.57
Licenses & Fees	3.95	20.05
Membership Expenses	0.77	1.04
Misc Expenses	2.43	10.18
Power & Fuel	55.57	63.93
Professional & Legal Expenses	40.45	21.60
R&D Expenses	57.08	6.03
Rent, Rates & Taxes	69.62	41.39
Repair & Maintenance Expenses	17.44	19.05
Security Expenses	9.44	15.05
Selling & Distribution Expenses	519.30	376.93
Software and Hardware Expenses	7.14	1.18
Stationery & Printing Expenses	4.07	4.65
Travelling & Conveyance Expenses	50.07	77.04
Total	948.65	821.08

23 Finance Costs

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2020 Rs.	For The Year Ended on 31-03-2019 Rs.
Interest On Long Term Borrowing	12.71	96.94
Interest On others	1.20	2.32
Other Borrowing Charges	4.41	4.31
Total	18.32	103.57

- 24 In compliance to Accounting Standard 20 on "Earning per share", the calculation of Earnings per Share (Basic and diluted) is as under:

Particulars	Year ended 31.03.2020	Year ended 31.03.2019
A. Profit/Loss attributable to Equity Shareholders	1,008.74	1,448.05
B. Weighted average No. of Shares	15,713,430	14,077,156
C. Nominal value of equity share	10	10
D. Basic EPS (Rs.) (A)/(B)	6.42	10.29
E. Diluted EPS(Rs.)	6.42	10.29

- 25 **Contingent Liabilities:-**
Contingent Liabilities, not provided for:
(As Certified by the Management)

Particulars	(Rs. In Lakhs)
	Current Period Rs.
Corporate Social Responsibility	50.32
Income Tax Law	1,000.38

- 26 In the opinion of the Management, Current Assets, Loans and Advances shall have the value on realization, in the ordinary course of the business, equal to the amount at which they are stated in the Balance Sheet.
- 27 In compliance of Accounting Standard 17 (AS-17) on "Segment Reporting" as notified under Companies Accounting Standard Rules, 2006, the company is engaged in manufacturing of Fast Moving Consumer Health Products (FMCHP). Considering the nature of business and financial reporting of the company, the company is operating only one segment and hence the segment reporting is not applicable.
- 28 The Company has adopted Accounting Standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed as under :

1. Amount of Liability in respect of Gratuity	
Particulars	FY 2019-20
Opening Balance of Obligation	17.88
Add :-	
Current Service Cost	3.82
Past Service Cost	-
Interest Cost	1.25
Banefits Paid	-
Acturial Gain (Loss)	(7.13)
Closing Balance	15.82

2. Amount of obligation recognized in statement of Profit & Loss	
Particulars	FY 2019-20
Current Service Cost	3.82
Past Service Cost	-
Interest Cost	1.25
Expected Return on plan assets	-
Net Acturial Losses (Gain) Recognised in the Year	(7.13)
Expenses Recognised In Statement of Profit & Loss	(2.06)

- 29 Previous years' figures are restated or regrouped or rearranged wherever necessary in order to confirm to the current years' grouping and classifications.
- 30 The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. In many countries, businesses are being forced to cease or limit their operations for long or indefinite period of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses, resulting in an economic slowdown.

In assessing the recoverability of Company's assets such as Investments, Loans, intangible assets, Goodwill, Trade receivable, Inventories etc. the Company has considered internal and external information upto the date of approval of these financial results. The company has performed sensitivity analysis on the assumptions used basis the internal and external information / indicators of future economic conditions and expects to recover the carrying amount of the assets and management has assessed, as a part of going concern assessment, impact of current event regarding COVID-19 and on entity's operations and forecasted cash flow and management has a positive view regarding the operations of the company.

31 **Additional Information**

a) Reporting under Micro, small & Medium Enterprise Development Act, 2016

The Company has initiated the process of identification of Creditors which falls under category of MSME, the dislouser relating to amount due to MSME are made to the extent information received.

b) Payment to auditor

Payment to Statutory Auditor as	For the year ended on 31st March, 2020 (Amount in Lakhs)	For the year ended on 31st March, 2019 (Amount in Lakhs)
Audit Fees	2.50	2.50

32 Details of Long Term Borrowings (Secured)

Sr. No.	Lender	Nature of facility	Loan Amount	Amount outstanding as at March 31, 2020	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Axis Bank	Car Loan	Rs. 69.00 Lakhs	Rs. 33.46 Lakhs	9.15%	Repayable in 60 Monthly Installment of Rs.1,43,735/- Each	Hypothecation of BMW car Purchased through Loan
2	HDFC Bank	Car Loan	Rs. 52.13 Lakhs	Rs.25.80 Lakhs	10.00%	Repayable in 60 Monthly Installment of Rs.1,10,787/- Each	Hypothecation of Benz car Purchased through Loan
3	Kotak Mahindra Bank	Car Loan	Rs. 85.00 Lakhs	Rs.35.62 Lakhs/-	8.25%	Repayable in 36 Monthly Installment of Rs.2,67,708/-Each	Hypothecation of porsche car Purchased through Loan
4	HDFC Bank	Car Loan	Rs. 18.14 Lakhs	Rs.16.43 Lakhs	9.50%	Repayable in 60 Monthly Installment of Rs.38,087/- Each	Hypothecation of Toyota car Purchased through Loan
5	HDFC Bank	Car Loan	Rs. 21.25 Lakhs	Rs.21.00 Lakhs	13.50%	Repayable in 60 Monthly Installment of Rs.48,900/- Each	Hypothecation of Mercedes car Purchased through Loan

Related Party Transaction

Names of Related Parties and Description of Relationship

Sr. No.	Nature of Relationship	Name of Related Parties
1	Key Management Personnel	Minto Purshotam Gupta
		Meenakshi M Gupta
		Hitesh Mohanalal Patel
		Yezdi Jal Batliwala
		Narendra Singh
		Savita Bhutani
		Uttam Kumar Singh
		Shreya Mitra
		Sheena Jain
2.	Relatives of Key Person	Mohak M Gupta
		Mohita M Gupta
3	Associates /Sister Concern/Enterprise	Nutricircle Limited
		Mintokashi Associates And Investments Private Limited
		Mintakashi FMCH Products India (OPC) Private Limited
		DWC Global PVT LTD
		Speciality Research And Life Sciences

Note: Related parties are identified by the Mangagemnt and relied up on by the Auditor.

(Rs. In Lakhs)

Sr. No.	Nature of Transaction	Associates/Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel	
		April'19 to March'20	April'19 to March'20	
(A)	Volume of Transactions			
1	<u>Remuneration to KMP & Relatives</u>			
	Minto Purshotam Gupta	--	65.50	
	Meenakshi M Gupta	--	45.31	
	Hitesh Mohanalal Patel	--	-	
	Yezdi Jal Batliwala	--	-	
	Narendra Singh	--	-	
	Savita Bhutani	--	-	
	Uttam Kumar Singh	--	11.95	
	Sheena Jain	--	3.95	
	Shreya Mitra	--	3.83	
	Mohak M Gupta	--	17.52	
	Mohita M Gupta	--	12.28	
	2	<u>Interest Expenses</u>		
	Yezdi Jal Batliwala		1.20	

Sr. No.	Nature of Transaction	Associates /Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel
		April'19 to March'20	April'19 to March'20
3	<u>Sales</u> Mintakashi FMCH Products India (OPC) Private Limited	5.07	

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

For & on behalf of Board of Directors

Keyur Shah
Proprietor
M.No. 153774

Minto P Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 31st July,2020

Uttam Kumar Singh
Chief Financial Officer
PAN-AFWPS4957D

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



Deccan Health Care Limited

247, Dwarakapuri, Punjagutta, Hyderabad. 500082, Telangana

Tel: 91 40 40144508 | www.deccanhealthcare.co.in